Ocular

Microbiology

and

Immunology Group

49th Annual Meeting

Forum Rooms 20-22

Caesars Palace

Las Vegas, Nevada

November 13, 2015

7:30 AM

ACKNOWLEDGEMENTS

OMIG thanks the following companies

for help in funding the costs

of the 2015 meeting:

Major Unrestricted Educational Grants:

Bausch & Lomb

TearLab

OMIG gives Special Recognition to

Charles & Morton Leiter of Leiters’ Pharmacy

for establishing & funding the

Harry Hirsch Leiter Award for best paper

And would also like to thank the following members

for their personal donations:

Deborah Langston, MD

Stella Robertson, MD

BOARD OF DIRECTORS

OMIG Board of Directors Irmgard Behlau, MD President

Bennie H. Jeng, MD Past President

Anat Galor, MD President-Elect

Bradley Fouraker, MD Secretary and

AAO Council Representative

Francis S. Mah, MD Executive Vice President

ARCHIVES OF OPHTHALMOLOGY

OMIG/JAMA Ophthalmology Collaboration

JAMA Ophthalmology will continue to serve as the official scientific journal of OMIG.

JAMA Ophthalmology will publish the abstracts accepted for presentation at the

annual meeting, as well as the Thygeson lecture and the Leiter award winning paper

(following peer review).

As an OMIG Society member, you will be eligible to receive full digital access to

JAMA Ophthalmology. (Free access will not include content of the Backfiles

Collection (issues published prior to 1998)). A reduced rate of $25 per year for

domestic ($65 per year for international) mail delivery for print subscriptions will also

be available for OMIG members. Members will be required to register on The JAMA

Network.com for digital access.

AGENDA

AGENDA

i

Ocular Microbiology and Immunology Group

49th Annual Meeting

Caesars Palace

November 13, 2015

Moderators: Irmgard Behlau, MD, and Anat Galor, MD

- AGENDA - 6:45 AM Registration 7:30 AM Introduction by Moderators 7:35 AM 2014 Harry Hirsch Leiter Award Recipient: Put The Preservative In The Bottle, Not In The Eye! R.A. Eiferman1, P.L. Tran2, T.W. Reid2, G.S. Schultz3, C. Batish3

1University of Louisville; 2Texas Tech University; 3University of Florida 7:43 AM 1. Epidemiology of Herpes Zoster Ophthalmicus: Recurrence and

Chronicity K.D. Tran1,2, M.M. Falcone3, D.S. Choi1,2, R. Goldhardt1,2, C.L. Karp2, J.L. Davis2,

A. Galor1,2 1Ophthalmology service, Miami Veterans Administration Medical Center, Miami,

FL; 2Bascom Palmer Eye Institute, University of Miami, Miami, FL; 3University of Miami Miller School of Medicine, Miami, FL

7:50 AM 2. Development of Herpes Zoster Ophthalmicus after Herpes Zoster

Vaccination S. Aggarwal, R. Muller, D. Pavan-Langston Cornea and Refractive Surgery Service, Department of Ophthalmology,

Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA

7:57 AM 3. Effect of Corneal Scar Location in Patients with Herpes Simplex Keratitis on Bilateral Corneal Nerve Alteration: An In Vivo Confocal Microscopy Study

C. Chirapapaisan1, R.T. Müller1,2, A. Cruzat1, B.M. Cavalcanti1, A. Jamali1,2, D.

Pavan-Langston1, P. Hamrah1,2 1Cornea and Refractive Surgery Service, Massachusetts Eye and Ear Infirmary,

Department of Ophthalmology, Harvard Medical School, Boston, MA; 2Cornea Service and Boston Image Reading Center, New England Eye Center/Tufts Medical Center, Tufts University School of Medicine, Boston, MA

AGENDA

ii

8:04 AM 4. Is Benzalkonium Chloride (BAK) Effective against Adenovirus? E.G. Romanowski, K.A. Yates, R.M.Q. Shanks, R.P. Kowalski The Charles T. Campbell Laboratory, UPMC Eye Center, Ophthalmology and

Visual Sciences Research Center, Eye and Ear Institute, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA

8:11 AM 5. Epstein-Barr Virus-Associated Scleritis Responsive to Valganciclovir: A

Case Report R. Garoon, A. Matoba Cullen Eye Institute, Baylor College of Medicine, Houston, TX 8:18 AM 6. Staphylococcus Caprae Polymicrobial Keratitis

D.J. Harris, III1 and D. J. Harris, Jr2 1Department of Ophthalmology & Visual Sciences, University of Kentucky, Lexington, KY; and 2Department of Surgery, The University of Tennessee Graduate School of Medicine, Knoxville, TN

8:25 AM 7. Molecular Epidemiology of Ocular Staphylococcus aureus Infections

P.J.M. Bispo, J. Wurster and M.S. Gilmore Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA

8:32 AM 8. Staphylococcus aureus Keratitis: Multi-Locus Sequence Typing and

Genome Sequencing to Identify Lineage, Virulence and Antibiotic Resistance Genes

I. Behlau1,2, J.N. Martin1,2, D. Lazinski1, S.R. Heimer2, K. Palmer3, E.M. Leonard2, A. Wright1, M.S. Gilmore2, C.H. Dohlman2, and A. Camilli1 1Molecular Biology & Microbiology and Ophthalmology, Tufts - Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA; 2Ophthalmology, Massachusetts Eye and Ear Infirmary/Schepens Eye Research Institute, Harvard Medical School, Boston, MA; 3Molecular & Cell Biology, University of Texas-Dallas, Dallas, TX

8:39 AM 9. Microbial Keratitis at an Urban Public Hospital: A 10-year Update

D.T. Truong and H.D. Cavanagh Department of Ophthalmology, UT Southwestern Medical Center, Dallas, TX

8:46 AM 10. Ocular Pathogens and Antibiotic Sensitivity of Bacterial Keratitis

Isolates at King Khaled Eye Specialist Hospital, Saudi Arabia - 2011-2014 D.U. Stone1,2, H. Al Dhaheri1, Mashael Tamimi1, M. Khan1, R. Khandekar 1 1King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia; and 2Wilmer Eye Institute of Johns Hopkins University

8:53 AM 11. Organ culture model for microbial keratitis in ex vivo rabbit and human

corneas

P. Garg1, Nagaveni S1, A. Pinnock2, S. Roy1, S. Rimmer2, I. Douglas2, S. MacNeil2 1LV Prasad Eye Institute, Hyderabad, India; and 2The University of Sheffield, Sheffield, United Kingdom

AGENDA

iii

9:00 AM 12. Corneal Endothelial Safety in Far Ultraviolet Light (222 nm)

Antimicrobial Ophthalmic Care

J.J. Rowsey1, E. Abdullayev2, B. Fouraker3, J. Michaelos1, S.E. Neister4, J. Neister4, S. Hudson4, D.A. Morgan4

1St. Michaels Eye and Laser Institute, Largo, FL; 2International Sight Restoration Eye Bank, Tampa, FL; 3Tampa General Hospital, Tampa, FL; 4Healthy Environment Innovations, Dover, NH

9:07 AM 13. Photodynamic Therapy-Potential as Alternative/Adjunctive Therapy for

MRSA Keratitis?

D. Miller, G. Amescua, F. Halili, Jr., A. Arboleta, H. Durkee, M. Taneja, K. Alawa, M.C. Aguilar, H.W. Flynn and J-M Parel

Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami, Miami, FL

9:14 AM 14. Intracameral Cross-Linked Hyaluronic Acid Plus Vancomycin —

Sustained Release and the First Step Towards Effective Dropless Eye Surgery R.A. Eiferman and D.P. DeVore University of Louisville, Louisville, KY

9:21 AM BREAK 9:36 AM 15. Diffusion of Moxifloxacin across Corneal Collagen Shield

K.M. Brothers; A.S. Grewal, D.K. Dhaliwal, R.M.Q. Shanks The Charles T. Campbell Laboratory, UPMC Eye Center, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA

9:43 AM 16. The Role of Scleral Debridement in Infectious Scleritis

L.A. Vickers, J.A. Irvine, H.Y. Hsu, O.L. Lee Doheny Eye Center of UCLA, UCLA Department of Ophthalmology, Los Angeles, CA

9:50 AM 17. Changing Azole Susceptibility in the Mycotic Ulcer Treatment Trial I

N.V. Prajna1, L. Prajna1, R. Rajaraman1, T. Krishnan1, A. Raghavan1, M. Srinivasan1, K.S. O’Brien2, M. Zegans6, S.D. McLeod3, N.R. Acharya2,3,4,T.M. Lietman2,3,4 J. Rose-Nussbaumer2,3,5 for the Mycotic Ulcer Treatment Trial Group 1Aravind Eye Care System at Madurai, Pondicherry and Coimbatore, India; 2Francis I. Proctor Foundation, San Francisco, CA; 3Department of Ophthalmology, University of California San Francisco, San Francisco, CA; 4Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA; 5Department of Optometry, University of California Berkeley, Berkeley, CA; 6Department of Ophthalmology, Dartmouth Medical School, Hanover NH

AGENDA

iv

9:57 AM 18. The Effect of Light Exposure on the Efficacy and Safety of Amphotericin

B in Optisol-GS Corneal Storage Media

K. Duncan1, J. Parker2, C. Hoover3, and B. Jeng1 1Department of Ophthalmology and Visual Sciences, University of Maryland School of Medicine, Baltimore, MD; 2University of Maryland Pathology Associates, PA, Baltimore, MD; 3SightLife, Seattle, WA

10:04 AM 19. Fungal Endophthalmitis after Descemet Stripping Automated

Endothelilal Keratoplasty Due to Endogenously Infected Grafts from the Same Donor

S. Palioura, K. Sivaraman, A. Sisse, J. Batlle, D. Miller, G. Amescua, A. Galor, and C.L. Karp

Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami, Miami FL

10:11 AM 20. Candida Interface Infections among a Cluster of Positive Fungal

Corneoscleral Rim Cultures Used in Descemet’s Stripping Automated Endothelial Keratoplasty

E. Tsui1,2, E. Fogel3, K. Hansen4, E.A. Talbot4,5, R. Tammer4, E.R. Daly4, J. Noble6, L. Caine6, J. Fogel7, M.E. Zegans1,5 1Dartmouth-Hitchcock Medical Center, Lebanon, NH; 2New York University School of Medicine, New York, NY; 3Concord Eye Center, Concord, NH; 4New Hampshire Department of Health and Human Services, Concord, NH; 5Geisel School of Medicine at Dartmouth, Hanover, NH; 6Concord Hospital, Concord, NH; 7Dartmouth College, Hanover, NH

10:18 AM 21. Fungal Keratitis and Endophthalmitis after using Gamma- Irradiated

Corneas as Carriers for Boston Type I Keratoprosthesis

M.D. Talati and T.F. Mauger Department of Ophthalmology and Visual Science, The Ohio State University Wexner Medical Center, Columbus, OH

10:25 AM 22. Hypochlorous Acid: A Candidate Prophylactic Antifungal Agent for

Boston Keratoprosthesis Patients

S. Odorcic, W. Haas, C.H. Dohlman Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA

10:32 AM 23. Initiation of Systemic Anti-Neoplastic Agents Contributing to Corneal Transplant Rejection? A Case Series

A. Rohr and A. Schrier Manhattan Eye, Ear, and Throat Hospital, Northshore-LIJ Health System Department of Ophthalmology, New York, NY

10:39 AM 24. Pure 0.01% Hypochlorous Acid Cleanser without Sodium Hypochlorite

Impurities for Treating Demodex Blepharitis

K. Najafi-Tagol, R. Najafi, C. Noorbakhsh, D. Debabov NovaBay Pharmaceuticals, Inc, Emeryville, CA

AGENDA

v

10:46 AM 25. Dry Eye Profiles in Patients with a Positive Elevated Surface Matrix

Metallopeptidase 9 Point of Care Test versus Negative Patients

V.S. Chang1, N.L. Lanza1,2, F. Valenzuela1, V.L. Perez1, A. Galor1,2 1Bascom Palmer Eye Institute, University of Miami, Miami, FL; 2Miami Veterans Administration Medical Center, Miami, FL

10:53 AM 26. Features of Neuropathic Ocular Pain in Dry Eye are Associated with

Chronic Comorbid Pain Syndromes (CPS)

H. Batawi1,2, D. Covington2,3, K.T. McManus2,3, B. Seiden2,3, E.R. Felix2,3, J. Kalangara2,3, W. Feuer2,3, D. Patin3, E.R. Martin3, K.D. Sarantopoulos3, R.C. Levitt3, A. Galor1,2 1Bascom Palmer Eye Institute, University of Miami; 2Miami Veterans Administration Medical Center; 3Department of Anesthesiology, Perioperative Medicine and Pain Management, University of Miami Miller School of Medicine, Miami, FL

11:00 AM 27. Low-Dose Topical Preservative-Free Dexamethasone 0.01% and 0.05%

for Treatment of Chronic Ocular Surface Disease Unresponsive to Commercially Available Steroids, Antibiotics, and Anti-Allergy Agents

A. Mallick, F. Chin, C. Shih, I. Udell, A. Steiner Hofstra-North Shore-LIJ School of Medicine, Department of Ophthalmology, Manhasset, NY

11:07 AM 28. Reduced Efficacy of Low-dose Topical Steroids in Dry Eye Disease

Associated with Ocular GVHD

A. Kheirkhah, T. Dohlman, U. Saboo, R. Dana. Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, MA.

11:20 AM 20th Thygeson Lecture: New Insights Into the Pathogenesis of Fungal Keratitis Eric Pearlman, PhD Professor Department of Ophthalmology and Department of Physiology and Biophysics Director, Institute for Immunology University of California, Irvine 12:05 PM Closing Comments and Awards 12:15 PM Business Luncheon, Genoa Room

ABSTRACTS

ABSTRACTS

- 1 -

Epidemiology of Herpes Zoster Ophthalmicus: Recurrence and Chronicity

K.D. Tran1,2, M.M. Falcone3, D.S. Choi1,2, R. Goldhardt1,2, C.L. Karp2, J.L. Davis2, A. Galor1,2 1Ophthalmology service, Miami Veterans Administration Medical Center, Miami, FL; 2Bascom Palmer Eye Institute, University of Miami, Miami, FL; 3University of Miami Miller School of Medicine, Miami, FL

Purpose: To provide a hospital-based epidemiology study on the prevalence of herpes zoster

ophthalmicus (HZO) with ocular involvement, and identify risk factors associated with recurrent and chronic disease. Design: Retrospective, hospital-based cohort study Participants: All patients evaluated in the Broward and Miami VA Healthcare System (MIAVHS) during

the study period January 1, 2010 and December 31, 2014 (N=119,569). Methods: Retrospective review of all patients in the MIAVHS with a confirmed HZ diagnosis from January 1, 2010 to December 31, 2014 using medical records review. Simple frequencies were calculated, and when appropriate, frequencies and means were compared using Chi-squared tests and two-sample t-tests, respectively. Kaplan-Meier survival curve was used to describe recurrence of disease, Cox proportional hazard analysis was used to evaluate risk factors for recurrence, and logistic regression to evaluate risk factors for chronicity. Main Outcome Measures: 1) Clinical diagnosis of HZO with eye involvement; 2) Recurrence of disease. Results: 119,569 patients total were evaluated at the MIAVHS within the study period. 90 patients had a

confirmed medically documented episode of HZO, and 60 had documented ocular involvement. First reactivation of HZ was most common in the 5th, 6th, and 7th decades of life (18%, 32%, 22%, respectively). The most frequent ophthalmic manifestations on first episode included conjunctivitis/episcleritis (44%), uveitis (26%), and epithelial keratitis (25%), followed by ocular hypertension (12%), stromal keratitis (11%), and endotheliitis (5%). 69% had an acute course, 17% had recurrent disease following resolution of the acute episode, and 13% had chronic disease that required either greater than 90 days to resolution, and/or never resolved. The 1, 2, and 5 year recurrence rates in those with initial resolution of disease were 5%, 8%, and 24%, respectively. Furthermore, the risk of recurrence continued to increase even after 5 years. Immune status, gender, age, and vaccination status were not significant predictors of recurrence. Risk factors associated with chronic disease were uveitis (OR=7.00, CI 1.78-27.56, p=0.01), elevated intraocular pressure (OR=8.00, CI 1.68-38.06, p=0.01), post herpetic neuralgia (PHN) (OR=4.50, CI 1.22-16.66, p=0.02), and increased number of ophthalmic complications on presentation (OR=2.57, CI 1.31-5.05, p=0.01). Conclusion: Traditionally studied as a monophasic illness, this study supports newer data that a significant proportion of patients experience disease recurrence and chronic sequelae. Further study is needed to guide preventative and therapeutic approaches in those with recurrent disease. Disclosue: S Support: Department of Veterans Affairs, Veterans Health Administration, Office of Research and

Development, Clinical Sciences Research and Development’s Career Development Award CDA-2-024-10S (Dr. Galor), NIH Center Core Grant P30EY014801, Research to Prevent Blindness Unrestricted Grant, Department of Defense (DOD- Grant#W81XWH-09-1-0675 and Grant# W81XWH-13-1-0048 ONOVA) (institutional), The Ronald and Alicia Lepke Grant, The Lee and Claire Hager Grant, The Jimmy and Gaye Bryan Grant, The Gordon Charitable Trust, and the Richard Azar Family Grant(institutional grants).

ABSTRACTS

- 2 -

Development of Herpes Zoster Ophthalmicus after Herpes Zoster Vaccination

S. Aggarwal, R. Muller, D. Pavan-Langston Cornea and Refractive Surgery Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA

Introduction: Herpes Zoster (HZ) vaccine is currently approved for people > 60 years of age to prevent and/or minimize HZ including Herpes zoster Ophthalmicus (HZO). While reactivation of keratouveitis after vaccination has been described as a rare event in patients with previous history of HZO, there have been no reported cases thus far in literature about development of HZO in patients after receiving Zostavax. The purpose is to report 4 such cases that developed HZO after being vaccinated for HZ. Methods: Patients were enrolled from 2010 to 2014 from the Cornea Service at Massachusetts Eye and Ear Infirmary. The patients’ previous history of HZ/HZO, HZ vaccination and clinical courses were recorded. Outcome measures studied were the age of incidence of HZ, HZ vaccination, clinical signs, symptoms and complications of HZO. Results: A total of 341 patients (114 males, 227 females) were enrolled, mean age being 56.0 ±17.6. Out of the 36 patients who got the vaccine, 4 patients who had no history of previous HZ or HZO or systemic immunocompromised states developed HZO, mean age of incidence being 67±14. Mean time between vaccination and development of HZO was 31± 3 months. Out of these, 3 patients had mild disease with no recurrences in a mean follow up of 21 months or significant complications like post herpetic neuralgia (PHN). 1 patient had a flare up of uveitis and PHN during a follow up of 2 years. Conclusion: We report 4 patients who developed HZO despite Zoster vaccination. While it is unlikely that the vaccine caused HZO based on the time period between vaccination and development of HZO, we cannot establish that with certainty. Clinically, these patients seemed to have less severe disease compared to unvaccinated patients. This is in agreement with the systemic literature which shows that HZ vaccination decreases the development and severity of HZ. Based on our data as a large tertiary care ophthalmic institute, it is indicative that while HZ vaccine does not completely eliminate risk of HZO, it may result in fewer long term complications even in patients who develop disease after vaccination. Large population studies based on systemic data are required to further elucidate vaccine safety and efficacy. Disclosure: N Support: N&V Johnstone Funds and Stevens Fund

ABSTRACTS

- 3 -

Effect of Corneal Scar Location in Patients with Herpes Simplex Keratitis on Bilateral Corneal Nerve Alteration: An In Vivo Confocal Microscopy Study

C. Chirapapaisan1, R.T. Müller1,2, A. Cruzat1, B.M. Cavalcanti1, A. Jamali1,2, D. Pavan-Langston1, P. Hamrah1,2 1Cornea and Refractive Surgery Service, Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, MA; 2Cornea Service and Boston Image Reading Center, New England Eye Center/Tufts Medical Center, Tufts University School of Medicine, Boston, MA

Purpose: Herpes simplex virus (HSV) can results in corneal scars in different locations. However it remains to be elucidated if the location of the scar has an effect on the degree of neurotrophic keratopathy. This study aimed to evaluate the effect of HSV corneal scar location on bilateral corneal nerve alteration and corneal sensation. Methods: 39 patients with either unilateral central HSV scar (CS) or peripheral HSV scar (PS) and 24 normal controls were recruited in this prospective, cross-sectional study. Subbasal corneal nerves density and function were analyzed bilaterally, using laser in vivo confocal microscopy (IVCM) and corneal esthesiometry centrally and peripherally. Results: The eyes with central and peripheral scars (CS and PS) revealed significant corneal nerve decrease in the central cornea (8.09±5.99 and 10.34±6.28 mm/mm2, p<0.0001) compared to controls (21.7±4.3). Similarly, they also showed significant subbasal nerve decrease in the periphery (p<0.0001) compared to controls (9.88±2.49). However, CS resulted in overall peripheral nerve decrease (5.15±2.81), whereas PS specifically affected only the affected peripheral area (4.22±3.08), but not the opposite side of the scar. Corneal sensation of CS and PS significantly decreased from normal (p<0.001) both centrally (3.61±2.26 and 3.02±2.2, p=0.08) and peripherally (3.55±2.0 and 2.61±2.0, p=0.46). In contralateral unaffected eyes, the nerve density was significantly lower in the central cornea of CS group (16.88±5.83, p< 0.05) and in the periphery of PS group, but only in the area corresponding to the scar of the affected eyes (7.20±3.48, p<0.05) compared to controls (center 21.73±4.37 and periphery 9.88±2.49). In contralateral eyes, significantly decreased corneal sensation was found only peripherally in the PS group, correlating with the scar area of the affected eyes (5.1, p<0.05). Conclusions: The location of HSV corneal scars is related to bilateral corneal nerve decrease as shown by IVCM. CS and PS influenced the decrease of subbasal nerve density and corneal sensation in both central and peripheral cornea of the affected eyes. Interestingly, the diminishment of corneal nerves and sensation was found locally in the contralateral unaffected eyes of patients with PS, corresponding and mirroring with the scar location in the affected eyes. Disclosure: N Support: NIH K08-EY020575 (PH), Research to Prevent Blindness Career Development

Award (PH), MEEI Foundation, Falk Medial Research Trust

ABSTRACTS

- 4 -

Is Benzalkonium Chloride (BAK) Effective against Adenovirus?

E.G. Romanowski, K.A. Yates, R.M.Q. Shanks, R.P. Kowalski The Charles T. Campbell Laboratory, UPMC Eye Center, Ophthalmology and Visual Sciences Research Center, Eye and Ear Institute, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA

Purpose: Benzalkonium chloride (BAK) is a common preservative used in ophthalmic medications. The goal of the current study was to determine whether BAK, at concentrations contained in ophthalmic medications, is effective in reducing titers of common ocular adenovirus (Ad) types. Methods: The direct inactivating activity of BAK was determined in duplicate trials by incubating high titer stocks of clinical isolates of Ad3, Ad4, Ad5, Ad7a, Ad8, Ad19, and Ad37 ATCC, with 0.001%, 0.003%, 0.005%, 0.01% BAK (concentrations found in ophthalmic medications) and a higher BAK concentration (0.1%) and control media for 1h at 33oC. Following incubation, standard plaque assays were performed on the reaction mixtures to determine the Ad titers after BAK or control treatment. Ad titers were Log10 converted and Log10 reductions in titers from the control were calculated. Results: A BAK concentration of 0.1% was virucidal (> 3 log10 decrease) for Ad3, Ad5, Ad7a, Ad19, and Ad37. 0.1% BAK reduced titers >1 Log10 but < 3 Log10 for Ad4 and Ad8. A >1 log decrease was demonstrated for BAK concentrations of 0.003%, 0.005% and 0.01% for Ad5 only. A <1 log10 decrease was noted for 0.001% BAK against all adenovirus types. Conclusions: BAK, at concentrations used in common ophthalmic medications, demonstrated variable efficacy in reducing titers of the Ad types tested. However, 0.1% BAK was effective in reducing titers of all of the Ad types tested. BAK at concentrations used in common ophthalmic medications appears not to be consistently effective as an agent against Ad, but higher concentrations should be further investigated as a topical treatment for adenoviral ocular infections. Disclosure: N Support: NIH Core Grant P30 EY008098, RPB, Eye & Ear Foundation

ABSTRACTS

- 5 -

Epstein-Barr Virus-Associated Scleritis Responsive to Valganciclovir: A Case Report

R. Garoon, A. Matoba Cullen Eye Institute, Baylor College of Medicine, Houston, TX

Purpose: To describe a case of Epstein-Barr virus (EBV) – associated scleritis responsive to valganciclovir. Methods: A patient with EBV – associated scleritis was retrospectively reviewed. Results: A 58 year old woman was referred with a 25 year history of recurrent bouts of bilateral episcleral and scleral inflammation. An evaluation by a rheumatologist had been negative. The inflammation had gradually become more persistent. At the time of referral she reported a 15 month bout of bilateral scleritis, poorly responsive to topical nepafenac, loteprednol, prednisolone, and oral ibuprofen and methylprednisolone. Slit lamp evaluation revealed bilateral diffuse scleral inflammation with moderate tenderness. There were no nodules, no areas of thinning, ulceration, or avascularity. The corneas were clear. CBC, HSV and VZV serologies were unremarkable. Antibody titer for EBV VCA was > 750 U/mL (nl <18), EBV nuclear antigen 512 U/mL (nl <18), EBV early antigen 77.8 U/mL (nl <9.0). Additional workup by a rheumatologist was again negative. The patient was treated with difluprednate QID and oral ibuprofen. The patient had a mild initial response but had rapid increase in inflammation upon taper of topical difluprednate. After 3 months, the rheumatologist recommended therapy with azathioprine. Repeat EBV serologies revealed persistent elevation. Oral valganciclovir was initiated instead. Over the course of one month, there was marked improvement of scleritis, allowing taper of topical steroid. The patient also reported significant improvement of chronic severe fatigue. Conclusion: To our knowledge, this is the first case of EBV-associated scleritis which demonstrated a response to antiviral therapy. This case supports the hypothesis that EBV is a cause of scleritis. Disclosure: N

ABSTRACTS

- 6 -

Staphylococcus Caprae Polymicrobial Keratitis

D.J. Harris, III1 and D. J. Harris, Jr2 1Department of Ophthalmology & Visual Sciences, University of Kentucky, Lexington, KY; and 2Department of Surgery, The University of Tennessee Graduate School of Medicine, Knoxville, TN

Purpose: To describe a case of polymicrobial keratitis, caused in part by Staphylococcus caprae, an organism not previously reported as a human ocular pathogen. Method: Retrospective case report. Results: A 65 year-old diabetic female long-term daily contact lens wearer presented to her ophthalmologist with acute pain and decreased vision in the right eye. After 30 days of empiric treatment of the large corneal infiltrate and ulcer with topical moxifloxacin, erythromycin, natamycin, and fortified gentamicin, she was referred because of progressive stromal infiltration and thinning. Culture of corneal scrapings performed at that time rapidly grew Staphylococcus caprae, sensitive to vancomycin. The eye at first improved under treatment with topical fortified vancomycin and systemic fluconazole, but the infiltrate and hypopyon increased during the second week of treatment. Fungal cultures of the original scrapings began to grow Paecilomyces lilacanus, and a central descemetocele formed. A therapeutic penetrating keratoplasty was performed. Histopathology of the resected cornea revealed fungal elements but no bacteria. The patient had an uneventful recovery with no recurrence of keratitis and a clear graft. Conclusions: Staphylococcus caprae, a coagulase-negative organism usually associated with goats, has rarely been reported in human bone and joint infections, but never as an eye pathogen. In this polymicrobial case, with no known exposure to goats, eradication of the bacterial component, confirmed by histopathology, probably caused transient improvement, but the fungal component necessitated a penetrating graft. This case demonstrates that failure of keratitis to respond to antibiotics may result not only from resistance, but also from a second unsuspected organism. It remains unknown whether Staphylococcus caprae can be a corneal pathogen alone. Disclosure: N

ABSTRACTS

- 7 -

Molecular Epidemiology of Ocular Staphylococcus aureus Infections

P.J.M. Bispo, J. Wurster and M.S. Gilmore Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA

Purpose: Staphylococcus aureus is a common cause of severe and difficult-to-treat ocular infections because of its virulence and antibiotic resistance. In this study, we aimed to determine the genetic relatedness of methicillin-susceptible (MSSA) and –resistant S. aureus (MRSA) recovered in 2014 from eye and periocular infections. Methods: A total of 71 ocular S. aureus isolates, 30 MRSA and 41 MSSA, were subjected to multilocus sequence typing. MRSA isolates were typed for SCCmec and screened for the presence of the panton-valentine leukocidin (PVL). Antibiotic resistance was also determined. Results: MSSA isolates fell into 21 different sequence types, most of which were associated to clonal complex CC30 (12.2%) and to somewhat related CCs including CC1 (9,7%), CC5 (9,7%), CC15 (9,7%), CC72 (9,7%), CC25 (7.3%) and CC8 (7.3%). Strains belonging to CC398 (7.3%), widely found in livestock-associated infections, were also isolated. SCCmec type IV was predominant (70%) among MRSA, followed by SCCmec type II (30%). SCCmec type IV isolates were frequently PVL-positive (76.2%) and mainly associated with CC8, while type II isolates were PVL-negative and grouped within CC5. Higher levels of resistance to lincosamides, macrolides and fluoroquinolones were found in MRSA in comparison to MSSA. While 38% of SCCmec type IV isolates were resistant to 3 drug classes, with the remaining resistant to ≤2 classes, all SCCmec II isolates were resistant to at least 4 drug classes. Interestingly, SCCmec type II isolates were commonly isolated from keratitis and SCCmec types IV were more predominant in orbital abscess and cellulitis, suggesting differences in ocular tissue tropism among distinct MRSA clones. Conclusions: distribution of MRSA lineages is consistent with a model where CC8 PVL-positive strains are better able to colonize and invade skin and soft tissues, resulting in infections such as orbital abscess, whereas CC5 type strains are better able to persist in the face of corneal defenses and infect at that site. Disclosure: S Support: NIH grants EY024285, AI083214. CAPES, Brazil (P.J.M.B. Grant #9775-13-7).

ABSTRACTS

- 8 -

Staphylococcus aureus Keratitis: Multi-Locus Sequence Typing and Genome Sequencing to Identify Lineage, Virulence and Antibiotic Resistance Genes

I. Behlau1,2, J.N. Martin1,2, D. Lazinski1, S.R. Heimer2, K. Palmer3, E.M. Leonard2, A. Wright1, M.S. Gilmore2, C.H. Dohlman2, and A. Camilli1 1Molecular Biology & Microbiology and Ophthalmology, Tufts - Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA; 2Ophthalmology, Massachusetts Eye and Ear Infirmary/Schepens Eye Research Institute, Harvard Medical School, Boston, MA; 3Molecular & Cell Biology, University of Texas-Dallas, Dallas, TX

Purpose: S. aureus is an opportunistic pathogen. It resides as a normal commensal of the human skin and nasopharynx, yet S. aureus infection appears to be predominantly caused by only a subset of the organisms. Sequence-based methods allow us to track epidemiological lineages. Whole genome sequencing enables us to identify new virulence and/or antibiotic resistance genes associated with keratitis. Methods: S. aureus clinical isolates were prospectively collected from the Boston area. The diagnosis of clinical keratitis and associated risk factors was by medical record review. Keratitis-associated S. aureus strains were assessed for: 1) antibiotic susceptibility by CSLI standards, 2) biofilm robustness by gentian violet staining, 3) genetic lineage, and 4) whole genome sequencing was performed using Illumina sequencing technology. Results: Risk factors included trauma, prior surgery, soft contact lens wear, and the presence of a surgical implant or environmental foreign body; 25% had no identifiable risk factor. Prior antibiotic usage did correlate strongly with methicillin-resistance. More than one-third of all the S. aureus keratitis-associated isolates were caused by a single clone, ST5, with both methicillin-sensitive and -resistant S. aureus strains represented. Using a patented linker and paired-end library construction, whole genome sequencing was performed inexpensively and provided insight into virulence and antibiotic resistance genes. Conclusions: These results suggest that there may be specific S. aureus lineages that possess genotypic characteristics that enable S. aureus to more effectively cause sight-threatening keratitis and other surface-associated (biofilm) infections. Additionally, new genome sequencing technology can give us insight into novel virulence traits that may be uniquely associated with different ocular and biofilm infections. Further work will explore the feasibility of cost-effective, real-time genomic sequencing technology into clinical application for hospital microbiology laboratories. Disclosure: N

ABSTRACTS

- 9 -

Microbial Keratitis at an Urban Public Hospital: A 10-year Update

D.T. Truong and H.D. Cavanagh Department of Ophthalmology, UT Southwestern Medical Center, Dallas, TX

Purpose: To review the recent epidemiology, risk factors, microbiology, and treatment of microbial keratitis at an urban public hospital with comparison to similar findings a decade earlier at the same hospital. Methods: Retrospective chart review of cases in the 5-year interval 2009 through 2014 compared to previously published cases 2000 through 2004 [Eye & Contact Lens 33(1): 45–49, 2007]. Primary outcome measures included vision, risk factors, culture and sensitivities, treatment, and complication rates. Results: From 2009-2014, 165 eyes with microbial keratitis have been identified. Contact lens wear, ocular trauma, and pre-existing ocular surface diseases were the most common risk factors. The culture and recovery rates were 66% and 69% respectively. Gram-positive organisms represented 59%, gram-negative organisms 30%, fungal organisms 10%, and acanthamoeba <1% of corneal isolates. No common corneal pathogens were resistant to aminoglycosides or vancomycin. Fluoroquinolone resistance was not routinely determined for most cultures. 35% of cases were initially treated with fortified antibiotics, 51% with fluoroquinolone monotherapy, and 5% with antifungals. 24% of cases were admitted to the hospital. At resolution, average BCVA was 20/63 [logMAR 0.50] with 10% of cases resulting in light perception or worse vision. The perforation rate was 6%. 10% of cases underwent urgent penetrating keratoplasty and 2% of cases underwent urgent enucleation or evisceration. Compared to prior study, significant differences were: (1) lower culture but higher recovery rate, (2) lower admission rate, (3) more gram-positive and fewer gram-negative organisms, (4) lower resistance of coagulase-negative staphylococcus to aminoglycoside antibiotics, (5) improved BCVA at resolution [20/231], and (6) lower associated complication rates. Conclusions: Microbial keratitis remains a challenging infection to treat in the urban public hospital setting. The microbiologic spectrum has shifted over the past decade towards gram-positive and away from gram-negative organisms. Patient outcomes have not worsened despite a shift away from routine culture and inpatient treatment. Disclosure: N Support: NIH EY020799, Research to Prevent Blindness

ABSTRACTS

- 10 -

Ocular Pathogens and Antibiotic Sensitivity of Bacterial Keratitis Isolates at King Khaled Eye Specialist Hospital, Saudi Arabia - 2011-2014

D.U. Stone1,2, H. Al Dhaheri1, Mashael Tamimi1, M. Khan1, R. Khandekar 1 1King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia; and 2Wilmer Eye Institute of Johns Hopkins University

Background: The empiric treatment of microbial keratitis relies upon knowledge of the relative frequencies of causative organisms and their susceptibility to available antibiotics. In many populations there has been a progressive development of antibiotic resistance. The factors that influence these changes may be related to macro influences, such as access to health care, industrialization, and inpatient health care, as well as patient-specific variables such as previous antibiotic use or hospitalization. Methods: To evaluate the recent trends in the organisms obtained from cultures of patients with microbial keratitis, as well as patterns of antibiotic sensitivity, we performed a retrospective study of all bacterial isolates from patients with microbial keratitis at the King Khaled Eye Specialist Hospital from 2011-2014. Results: There were 3,506 bacterial isolates during the study period. Gram positive bacteria accounted for 91.4% of isolates. They mainly included Staphylococcus epidermidis 962 (47.2%), Other Coagulase-negative staphylococci 289 (14.2%), Staphylococcus aureus 237 (11.6%), and Streptococcus pneumonia 159 (7.8%). Pseudomonas aeruginosa was the most common gram negative isolate (6.0%). All tested isolates maintained 100% sensitivity to vancomycin over the study duration. Oxacillin resistance was increasingly found in S aureus (14.8% in 2011 to 27.8% in 2014. P<0.05) but was without significant change in Staph epidermidis and other coagulase-negative Staph (range 19.4-32.0%). S aureus isolates showed an increase in moxifloxacin resistance from 2011 – 2014, increasing from 0 to 14% (P=0.05). All S pneumoniae isolates were sensitive to chloramphenicol, moxifloxacin and ofloxacin; resistance to other antibiotics remained stable, including penicillin (range 24.5% - 42.9%) and erythromycin (34.0-60.0%). Pseudomonas aeruginosa isolates were resistant to ceftazidime in 5.6%, ciprofloxacin 4.9% and gentamicin 4.9%, with no significant change during the study period. Conclusions: While the rates of antibiotic resistance are lower than reports from many European and North American cohorts, there appears to be a trend of increasing resistance to some antibiotics. This may be related to “westernization” of regional health care, with increasing access to care and utilization of antibiotics. The low prevalence of gram negative bacterial keratitis, increasing prevalence of MRSA and fluoroquinolone resistant S aureus may be taken into consideration when initiating empiric therapy. Disclosure: N

ABSTRACTS

- 11 -

Organ culture model for microbial keratitis in ex vivo rabbit and human corneas

P. Garg1, Nagaveni S1, A. Pinnock2, S. Roy1, S. Rimmer2, I. Douglas2, S. MacNeil2 1LV Prasad Eye Institute, Hyderabad, India; and 2The University of Sheffield, Sheffield, United Kingdom

Purpose: The aim of the present study was to develop a reproducible model of corneal infection using ex vivo organ culture of rabbit and human corneas. Methods: Wild brown rabbit and cadaveric human corneas unsuitable for transplant were maintained in corneal organ culture for 24 or 48 hours at 37°C after being wounded with a scalpel, or injected intrastromally with 108 Cfu of Staphylococcus aureus, Pseudomonas aeruginosa or Candida albicans. Corneas were homogenized and subjected to microbial plate counting and the results are presented as colony- forming units (CFU). Corneas were histologically processed and sections were Gram-stained. Corneas not exposed to microbes were used as controls. Results: Using the scalpel wounding method, CFU/cornea recovered after 24 hours were 5.1±1x105 and 1.4±4.2x106, (n=5), for S. Aureus, 1.9±2.9x107 and 2.8±3.2x107, (n=5) for P. aeruginosa and 3.0±6.0x105 and 2.0±7.8x106 (n=3) for C. albicans from rabbit and human corneas respectively. The injection method yielded a 10-fold increase (p<0.05) in detectable organisms compared with the scalpel method. There was no significant difference in CFU/cornea after 48h. Histology of the scalpel-wounded and injection models indicated extensive infiltration of P. aeruginosa throughout the entire cornea, with less infiltration observed for S. aureus and C. albicans. Conclusions: Both scalpel wounding and injection methods were suitable for inducing infection in corneas maintained in organ culture. Differences between the CFU/cornea for rabbit and human corneas may be due to the expression of different antimicrobial peptides or surface receptors influencing colonization of the tissue. These simple and reproducible ex vivo models will be useful as an alternative to monolayer cells and in vivo models for investigating microbial keratitis. Disclosure: C = Allergan India, NovaBay Support: Wellcome trust, UK

ABSTRACTS

- 12 -

Corneal Endothelial Safety in Far Ultraviolet Light (222 nm) Antimicrobial Ophthalmic Care

J. J. Rowsey1, E. Abdullayev2, B. Fouraker3, J. Michaelos1, S.E. Neister4, J. Neister4, S. Hudson4, D.A. Morgan4

1St. Michaels Eye and Laser Institute, Largo, FL; 2International Sight Restoration Eye Bank, Tampa, FL; 3Tampa General Hospital, Tampa, FL; 4Healthy Environment Innovations, Dover, NH

Purpose: To determine the corneal endothelial safety of 222 nm Far Ultraviolet Light on healthy eye bank corneas and correlate this wavelength safety to the antimicrobial activity of known cornea pathogens. Methods: Five eye bank eye corneas were placed with the endothelial surface in the collimated path of a 222nm Far UV lamp generator. Endothelial exposure was created by placing corneas 40 mm from the UV light source for 10, 20, 30, 60 seconds and ten minutes respectively. Corneal endothelial safety was evaluated by specular microscopy at 3 hours, 24 hours, 5 days, and 6 days post irradiation on each cornea. Results: No endothelial toxicity was noted at 10 and 20 seconds of Far UV exposure. Early endothelial changes were noted at 30 seconds at 24 hours post treatment and at 60 seconds as soon as 3 hours post treatment. Entire endothelial damage was noted at ten minutes exposure after 24 hours. Conclusions: 222 nm Far UV light exposure of the cornea is safe for the endothelium at 10 and 20 seconds. Our prior microbiologic studies have demonstrated 4 log killing of staph aureus, and pseudomonas aeruginosa within 6 seconds of exposure and candida albicans at 20 seconds. The margin of safety for antimicrobial treatment and the corneal endothelium may be auspicious for 222nm Far UV clinical intervention. Disclosure: C (Rowsey, Abdullayev, Morgan)

N (Fouraker, Michaelos) O, P (S. Neister, J. Neister, Hudson)

ABSTRACTS

- 13 -

Photodynamic Therapy-Potential as Alternative/Adjunctive Therapy for MRSA Keratitis?

D. Miller, G. Amescua, F. Halili, Jr., A. Arboleta, H. Durkee, M. Taneja, K. Alawa, M.C. Aguilar, H.W. Flynn and J-M Parel

Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami, Miami, FL

Purpose: Increasing clinical and laboratory resistant Staphylococcus aureus isolates recovered from keratitis is problematic and part of the growing public health crisis in antibiotic resistance. Limited topical antibiotics compromise effective patient management and optimal outcomes. Our purpose is to update the increasing resistant trends and changing epidemiology of MRSA keratitis in South Florida and to highlight Rose Bengal photodynamic therapy (PDT-RB) as a potential therapeutic alternative for the treatment of Staphylococcus aureus keratitis. Methods: Laboratory records were reviewed and convenience sets of Staphylococcus aureus keratitis isolates were analyzed for MRSA prevalence (1990-June-2015, N= 941), mec A type (N=60) and emerging co-resistance (N=196, 2011-June 2015) to common topical antibiotics. We evaluated combinations of the photosensitizer Rose Bengal (RB, concentrations .1%, .03%) and light (activated-ambient and green-518 nm) vs no light (dark-unactivated) to kill or inhibit growth of fluoroquinolone sensitive/resistant MRSA strains plated on nutrient agar (1.5 x 104 cfu/ml) post 30 minute exposure. Results: The prevalence of MRSA keratitis increased by 62% from base line (1990-1994, 13.4%) to 35.7% for the last 18 months (2014-June 2015). Eighty percent of the MRSA were healthcare associated, mecA, type II (USA100). In vitro susceptibility to moxifloxacin was less than 90% for both MSSA (N=126, 81%) and MRSA (N=70, 9%). Co-resistance were more likely to be associated with MRSA isolates for erythromycin (93% vs 41%), gentamicin (7% vs 1%) and trimethoprim sulfa (10% vs 2%). All isolates remain susceptible in vitro to vancomycin. At 24 hours, there was complete inhibition of both MRSA strains with the 0.1% RB under activated and unactivated conditions. Killing was observed only under activated conditions for the lower (0.03%) concentration. Conclusions: Options for treatment and management of keratitis due to both MSSA and MRSA isolates are becoming more restrictive. We confirm that healthcare is a major risk factor for MRSA keratitis. Photodynamic therapy with Rose Bengal was effective in vitro in killing and or inhibiting MRSA and could have in vivo applications. Disclosure: N Support: NIH Center grant P30EY14801, Research to Prevent Blindness

ABSTRACTS

- 14 -

Intracameral Cross-Linked Hyaluronic Acid Plus Vancomycin —Sustained Release and the First Step Towards Effective Dropless Eye Surgery

R.A. Eiferman and D.P. DeVore

University of Louisville, Louisville, KY Purpose: While intracameral antibiotic injections have been advocated as prophylaxis against endophthalmitis, they are quickly diluted by fresh aqueous humor as well as lost via outflow through the trabecular meshwork. We have devised a unique method to cross-link hyaluronic acid that traps antibiotic in a “molecular cage”. This provides a biodegradable slow release delivery system that delivers vancomycin at bacteriocidal levels for 72 hours Method: Hyaluronic acid is cross-linked by a novel process, 1 mg of fluoroscein tagged vancomycin is added. This immediately forms a small viscoelastic droplet which contains the antibiotic. The mixture is placed in 1 cc normal saline and aliquots are withdrawn at 1, 6, 12, 24, 48 and 72 hours. The studies were done in triplicate. Vancomycin levels were measured in a fluorometer at each time point. Results: The cross-linked hyaluronic acid containing vancomycin slowly hydrolyzed releasing the antibiotic. At one hour, the vancomycin measured 225 ug. At 6 and 12 hours, the vancomycin averaged 100 ug. At 24 hours, the vancomycin averaged 70 ug; at 48 hours, the vancomycin levels averaged 50 ug and at 72 hours, the vancomycin levels averaged 35 ug. At all time points, the vancomycin was above bacteriocidal levels for most pathogens Conclusion: The use of cross-linked hyaluronic acid can provide a sustained release of medication. When placed in the anterior chamber, this method may eliminate the need for patients to self administer post operative antibiotic eye drops Disclosure: P

ABSTRACTS

- 15 -

Diffusion of Moxifloxacin across Corneal Collagen Shield

K.M. Brothers; A.S. Grewal, D.K. Dhaliwal, R.M.Q. Shanks The Charles T. Campbell Laboratory, UPMC Eye Center, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA

Purpose: To investigate diffusion of moxifloxacin through collagen corneal shields compared to contact lenses. Methods: Using an in vitro model, the diffusion of moxifloxacin through silicone hydrogel contact lenses and corneal collagen shields was measured. To determine overall moxifloxacin absorption and diffusion, each contact lens and collagen shield was first soaked in PBS for 5 minutes, during which a “skewer” was inserted through the lens or shield for easy transfer, followed by a 10 minute soak in moxifloxacin. Next, the lens or shield was briefly dipped again in PBS for 1 second to remove excess moxifloxacin and transferred to a final volume of PBS in a UV cuvette for spectrophotometric readings. The contact lens and collagen shields were removed from the cuvette during each reading and promptly replaced immediately thereafter. Moxifloxacin release was measured at an absorbance of 293 nm using a spectrophotometer at 30 seconds, 2, 5, 10, 30, 60, and 120 minutes. The amount of moxifloxacin was calculated by correlating experimental values to a standard curve. Results: Diffusion of moxifloxacin was significantly greater from collagen shields than contact lenses at every time point tested. Conclusions: Our preliminary data indicate collagen shields may be a useful tool for administration of fluoroquinolones to the cornea. Disclosure: S Support: Research to Prevent Blindness, Eye and Ear Institute of Pittsburgh, NIH grant

EY017271-06A1, NIH grant AI085570, NIH grant EY024785, NIH Core Grant EY08098, Collagen Shields were kindly donated by Oasis Medical.

ABSTRACTS

- 16 -

The Role of Scleral Debridement in Infectious Scleritis

L.A. Vickers, J.A. Irvine, H.Y. Hsu, O.L. Lee Doheny Eye Center of UCLA, UCLA Department of Ophthalmology, Los Angeles, CA

Purpose: To demonstrate the role of scleral debridement in a series of cases of infectious scleritis, and its potential usefulness in avoiding poor outcomes. Methods: The medical records of patients with culture-proven infectious scleritis were reviewed retrospectively. Microbial culture results, therapeutic approach, time to scleral debridement if performed, anatomic outcomes including development of scleral perforation, choroidal detachment, need for enucleation, and final visual outcome were compared. Early scleral debridement was defined as being carried out before scleral perforation, and late debridement when done after perforation occurred. Results: Six eyes of 6 patients were identified as having infectious scleritis. Most patients had prior surgery as a risk factor, with 3 patients having undergone prior pterygium surgery with mitomycin-C (MMC), one trabeculectomy/Ex-Press shunt with MMC, one with exposure keratopathy leading to a sclerokeratitis and one with autoimmune scleral melt with secondary infection. Cultures were positive for Pseudomonas in three eyes, Aspergillus in one eye, Streptococcus in one eye and Staphylococcus in one eye. In addition to antibiotic treatment, scleral debridement was done in 5 eyes, 4 eyes with early debridement and one eye with late debridement after a small perforation. Three eyes with Pseudomonas scleritis developed choroidal detachments and one eye with Streptococcus scleritis developed a serous retinal detachment. Three of these eyes underwent early debridement with subsequent resolution of the choroidals and retinal detachment, but without significant final visual improvement and final visual acuities ranging from counting fingers to 20/150. The third eye underwent late debridement and was eventually enucleated. All eyes that underwent early debridement did not require enucleation. Conclusions: Infectious scleritis is a rare and eye-threatening condition frequently associated with poor outcomes. In addition to antibiotic use, scleral debridement performed prior to scleral perforation may have a role in avoiding enucleation. However, complications such as choroidal or retinal detachment can prohibit visual recovery even in cases of anatomic recovery. Disclosure: N (Vickers, Irvine, Hsu)

S, C (Lee)

ABSTRACTS

- 17 -

Changing Azole Susceptibility in the Mycotic Ulcer Treatment Trial I

N.V. Prajna1, L. Prajna1, R. Rajaraman1, T. Krishnan1, A. Raghavan1, M. Srinivasan1, K.S. O’Brien2, M. Zegans6, S.D. McLeod3, N.R. Acharya2,3,4, T.M. Lietman2,3,4 J. Rose-Nussbaumer2,3,5 for the Mycotic Ulcer Treatment Trial Group 1Aravind Eye Care System at Madurai, Pondicherry and Coimbatore, India; 2Francis I. Proctor Foundation, San Francisco, CA; 3Department of Ophthalmology, University of California San Francisco, San Francisco, CA; 4Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA; 5Department of Optometry, University of California Berkeley, Berkeley, CA; 6Department of Ophthalmology, Dartmouth Medical School, Hanover NH

Introduction: The development of multiple-triazole resistance in pathogenic filamentous fungi has become an increasing clinical concern and has been shown to increase the risk of treatment failure. The Mycotic Ulcer Treatment Trial I, was a NIH-funded double-masked, randomized controlled trial that found natamycin to be superior to voriconazole in the treatment of filamentous fungal ulcers, and in particular those infected with Fusarium species. In this non-pre-specified subgroup analysis, we will investigate how azole resistance patterns changed over the duration of the MUTT I clinical trial. Methods: Smear-positive filamentous fungal corneal ulcers patients with visual acuity between 20/40 and 20/400 enrolled at Aravind Eye Care System, were randomized to receive 5% topical natamycin or 1% topical voriconazole. Baseline scrapping and cultures were obtained from all study participants. Using the standards set by the Clinical and Laboratory Standards Institute, speciation and analysis of minimum inhibitory concentration (MIC) to natamycin and voriconazole were performed on all positive fungal samples collected. Multiple linear regression was performed to analyze the association between the date enrolled in the study, as our primary predictor of interest and baseline MIC, adjusting for infectious organism. In order to get fold change in MIC per year, the antilog was taken of the coefficient multiplied by 365. Results: Between April 3, 2010 and December 31st, 2011 positive fungal cultures were obtained on 256/323 (79%) of study participants. MIC data were available for 221/323 (68.4%), as 35 samples did not grow during susceptibility testing. The average voriconazole MIC for all organisms over the entire duration of the study was 3.19 (SD 3.62). Mean Log2-transformed voriconazole MICs were 4.69 (SD 3.79) for Fusarium, 0.99 (SD 1.24) for Aspergillus and 1.47 (SD 2.83) for all other organisms. There was a 2.14-fold increase in voriconazole MIC per year after controlling for infectious organism (95% CI 1.13 to 4.56, P = 0.02). This association was not found when looking at natamycin MICs from baseline cultures after controlling for infectious organism (1.26, 95% CI 0.13 to 12.55, P = 0.852). Discussion: Susceptibility to voriconazole apparently decreased even over the relatively short enrollment period of a clinical trial. This may be more related to increased resistance of environmental fungi rather than previous treatment with azoles, as presenting on an azole was not itself a risk factor for resistance. These microbiological findings highlight the primary clinical trial result that natamycin is superior to voriconazole in the treatment of filamentous fungal keratitis. A trend of increasing azole resistance could impact treatment of human mycoses. Disclosure: S

ABSTRACTS

- 18 -

The Effect of Light Exposure on the Efficacy and Safety of Amphotericin B in Optisol-GS Corneal Storage Media

K. Duncan1, J. Parker2, C. Hoover3, and B. Jeng1 1Department of Ophthalmology and Visual Sciences, University of Maryland School of Medicine, Baltimore, MD; 2University of Maryland Pathology Associates, PA, Baltimore, MD; 3SightLife, Seattle, WA

Purpose: In contrast to the corneal storage medium used in Europe, the most commonly used corneal storage medium in the US, Optisol-GS, does not contain an antifungal additive. Given the increasing rate of postkeratoplasty fungal infection, we sought to find a concentration of antifungal additive that would be safe and efficacious in eliminating fungal contaminants from Optisol-GS. Because amphotericin B is degraded by light, we also sought to determine what effect light exposure has on its efficacy and safety. Methods: Vials of Optisol-GS were supplemented with Amphotericin B at 3 concentrations and then inoculated with C. albicans. Samples from each vial were plated on days 2, 7, and 14 and fungal colony counts were performed. To assess for toxicity of amphotericin B, donor corneas were placed in Optisol-GS supplemented with Amphotericin B. All corneas were evaluated for endothelial cell density and % intact epithelium on day 0, 7 and 14. Half of the Optisol-GS vials and donor corneas were kept in light protected conditions. Results: There was no growth of C. albicans in any amphotericin B supplemented vials on days 7 and 14. Minimal growth was observed at the lower concentrations on day 2 only. There was no significant difference in intact epithelium and endothelial cell density between the amphotericin B supplemented and control corneas. There was no difference in our data between the light exposed and light protected conditions. Conclusions: Our study confirms the antifungal efficacy and safety of amphotericin B in Optisol-GS. Consideration should be given to the addition of an antifungal to the corneal storage process in the US. Disclosure: S Support: 2014 Richard Lindstrom/EBAA Research Grant

ABSTRACTS

- 19 -

Fungal Endophthalmitis after Descemet Stripping Automated Endothelilal Keratoplasty Due to Endogenously Infected Grafts from the Same Donor

S. Palioura, K. Sivaraman, A. Sisse, J. Batlle, D. Miller, G. Amescua, A. Galor, and C.L. Karp Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami, Miami FL

Purpose: To report two cases with post-operative Candida albicans endophthalmitis after Descemet Stripping Automated Endothelial Keratoplasty (DSAEK) with grafts originating from the same donor. Methods: Retrospective case series of two patients with late post-operative fungal endophthalmitis after DSAEK with corneal grafts from the same donor. Results: Two patients with Fuchs’ dystrophy underwent uncomplicated DSAEK by two corneal surgeons at different surgery centers. Both patients received a cornea from the same donor who had a history of presumed pulmonary candidiasis without positive blood cultures. Both patients were referred to Bascom Palmer Eye Institute with multifocal infiltrates at the graft-cornea interface one month later. Despite immediate explantation of the DSEK lenticules and intraocular antifungal injections both patients progressed to develop fungal endophthalmitis with the same strain of Candida albicans. Following penetrating keratoplasty with intraocular lens explantation, pars plana vitrectomy and serial intraocular antifungal injections, both are doing well at 6 months post-operatively. Conclusions: Fungal endophthalmitis due to infected donor corneal graft presents a management challenge and should prompt careful follow up of both recipients from the same donor. Disclosure: N

ABSTRACTS

- 20 -

Candida Interface Infections among a Cluster of Positive Fungal Corneoscleral Rim Cultures Used in Descemet’s Stripping Automated Endothelial Keratoplasty

E. Tsui1,2, E. Fogel3, K. Hansen4, E.A. Talbot4,5, R. Tammer4, E.R. Daly4, J. Noble6, L. Caine6, J. Fogel7, M.E. Zegans1,5 1Dartmouth-Hitchcock Medical Center, Lebanon, NH; 2New York University School of Medicine, New York, NY; 3Concord Eye Center, Concord, NH; 4New Hampshire Department of Health and Human Services, Concord, NH; 5Geisel School of Medicine at Dartmouth, Hanover, NH; 6Concord Hospital, Concord, NH; 7Dartmouth College, Hanover, NH

Purpose: To describe two Candida interface keratitis infections occurring in the setting of positive donor rim cultures from pre-cut corneal tissue used for Descemet’s stripping automated endothelial keratoplasty (DSAEK) and the ensuing public health investigation. Methods: Following two clinical Candida interface keratitis infections, patients from 2012-2014 in the same surgical center were evaluated for bacterial and fungal rim cultures and subsequent infection. All cases of fungal infections occurring post-DSAEK were analyzed. Data included patient demographics, surgical technique, donor rim cultures, donor mate outcomes, clinical courses and outcomes. A review of the relevant literature was also undertaken. Results: From 2012-2014, among 99 DSAEK procedures performed, 7 (7.1%) of the donor rim cultures were positive for fungi. Use of this tissue with positive donor rim cultures resulted in two (28.6%) episodes of confirmed fungal interface keratitis, both Candida species, and presumptive treatment in an additional two patients. An investigation did not identify any breach in sterile technique or procedures. Our literature review of case report data documented 15 reports of post-operative fungal infection associated with DSAEK, of which 11 involved Candida spp. Conclusions: This report of correlated rim cultures and clinical infection suggest a need for re-evaluation of the utility of obtaining routine corneoscleral donor rim fungal culture. Furthermore, our cases along with those previously reported suggest that DSAEK utilizing pre-cut tissue may be particularly susceptible to infection with Candida spp. Disclosure: N

ABSTRACTS

- 21 -

Fungal Keratitis and Endophthalmitis after using Gamma- Irradiated Corneas as Carriers for Boston Type I Keratoprosthesis

M.D. Talati and T.F. Mauger

Department of Ophthalmology and Visual Science, The Ohio State University Wexner Medical Center, Columbus, OH

Purpose: To report 3 cases of fungal keratitis and/or endophthalmitis in patients after implantation of a Boston keratoprosthesis (Kpro) type I utilizing gamma irradiated sterile corneal grafts. Methods: A retrospective case series of Kpro cases using gamma irradiated sterile tissue. All cases were treated with prophylactic topical vancomycin and moxifloxacin. Bandage contact lenses were used post-operatively and replaced every 2-3 months after pretreatment with 5% povidine-iodine. Three cases were complicated by fungal infection and required subsequent explantation. Results: Three eyes developed fungal keratitis and/or endophthalmitis. The indication for Kpro implantation in each of these cases included corneal damage secondary to silicone oil, limbal stem cell deficiency, and multiple corneal graft failure. Cultures revealed infection with Fusarium spp. in two eyes, while the third case was due to Candida parapsilosis. All three cases required removal of the Kpro followed by penetrating keratoplasty with optisol stored fresh cornea ranging from 14-28 months after Kpro placement. No recurrence of infection occurred after transplantation with fresh donor cornea. Conclusion: To the best of our knowledge, previous studies have evaluated gamma-irradiated sterile corneal graft use for Kpros with no evidence of keratitis or endophthalmitis within a finite follow up period. Here, we present 3 cases of fungal infection requiring explantation of the Kpro followed by therapeutic penetrating keratoplasty with fresh cornea. Disclosure: N

ABSTRACTS

- 22 -

Hypochlorous Acid: A Candidate Prophylactic Antifungal Agent for Boston Keratoprosthesis Patients

S. Odorcic, W. Haas, C.H. Dohlman

Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA Purpose: To review the current literature on fungal keratitis and endophthalmitis following Boston Keratoprosthesis (KPro) implantation, and characterize the antifungal activity of 0.01% hypochlorous acid against fungi known to cause ocular infections. Methods: i) A literature review of reported cases of fungal keratitis or endophthalmitis in KPro patients from January 2001 to June 2015, ii) An in vitro time kill assay characterizing the fungicidal and sporicidal activity of 0.01% hypochlorous acid against a selection of medically relevant fungi. Results: Fifteen publications were identified, consisting of predominantly retrospective case series. Infection rates following KPro implantation ranged from 0.009-0.02 fungal infections per patient-year of follow-up. The largest single surgeon series reported an incidence of 2.4% for fungal endophthalmitis during a 10-year period. Causative organisms included both yeasts and molds, with Candida species, particularly C. parapsilosis causing the majority of infections in KPro patients in northern North America. Hypochlorous acid, 0.01%, is rapidly fungicidal, reducing the number of viable yeast cells or mold conidia by at least 99.99% within 60 seconds. Its broad-spectrum of activity extended to all molds (Acremonium kiliense, Aspergillus flavus, Aspergillus fumigatus, Fusarium solani, Mucor indicus) and yeast species (Candida albicans, Candida parapsilosis) tested. Conclusions: Fungal infections remain a lifelong concern in patients following KPro implantation. There is a pressing need for a standardized antifungal prophylaxis regime, particularly in the developing world where fungi are endemic and resources for treatment limited. The rapid broad-spectrum in vitro fungicidal activity of 0.01% hypochlorous acid against all fungi tested makes it a promising candidate as an antifungal prophylaxis agent in KPro patients. Disclosure: E

ABSTRACTS

- 23 -

Initiation of Systemic Anti-Neoplastic Agents Contributing to Corneal Transplant Rejection? A Case Series

A. Rohr and A. Schrier

Manhattan Eye, Ear, and Throat Hospital, Northshore-LIJ Health System, Department of Ophthalmology, New York, NY

Purpose: To report a case series of three patients that presented with episodes of corneal transplant rejection after recent initiation of systemic anti-neoplastic agents for various types of malignancies. Methods: Case 1 is an 85 year-old female with a history of Descemet’s stripping automated endothelial keratoplasty in the right eye in 2012 for pseudophakic bullous keratopathy. She presented in July 2015 complaining of decreased vision in the right eye after initiation of systemic chemotherapy (platinum/taxane compounds) for metastatic ovarian cancer. Exam was significant for decreased visual acuity of 20/150 (baseline 20/50) and 3+ corneal edema. Case 2 is a 60 year-old female with history of a penetrating keratoplasty in the left eye for keratoconus in 1997. She presented in April 2015 complaining of irritation in the left eye after starting immunotherapy (NYESO1) for melanoma. Visual acuity was 20/40 (baseline 20/30) with trace cell and keratic precipitates on left eye anterior segment exam. Case 3 is a 68 year-old female with history of bilateral penetrating keratoplasties in the 1970s for keratoconus, with repeat penetrating graft in the left eye in 2006. In June 2012, she complained of decreased vision in both eyes after initiation of hormone therapy (tamoxifen) for breast cancer. Exam demonstrated visual acuity of 20/500 and 20/70 in the right and left eyes respectively, (baseline of 20/80, 20/50) bilateral corneal edema and AC reaction. Results: All three cases were diagnosed with corneal transplant rejection (1 DSAEK, 3 PKs) within 4 weeks of initiation of various systemic anti-neoplastic therapies (chemotherapy, immunotherapy and hormonal therapy). All cases of rejection were treated with topical prednisolone acetate 1% four times a day in the affected eye +/- muro 128. Case 2 and 3 grafts recovered with treatment; Case 1 follow-up is pending. Conclusions: Patients with a history of a corneal transplant that plan to start systemic anti-neoplastic therapy may be at greater risk for rejection episodes. Close ophthalmology follow-up shortly after initiation of anti-cancer therapy may be warranted. Disclosure: N

ABSTRACTS

- 24 -

Pure 0.01% Hypochlorous Acid Cleanser without Sodium Hypochlorite Impurities for Treating Demodex Blepharitis

K. Najafi-Tagol, R. Najafi, C. Noorbakhsh, D. Debabov

NovaBay Pharmaceuticals, Inc, Emeryville, CA Purpose: Demodex is a common microscopic parasite associated with blepharitis which appears to arise from Staphylococci that are carried on the surface of the parasites and Bacillus oleronius found inside the mites. A case of an ocular surface disease patient with a Demodex infestation treated with AVENOVA (0.01% pure hypochlorous acid in saline pH 4 without sodium hypochlorite impurities) is described. We also present in vitro bactericidal activity of AVENOVA against bacteria associated with Demodex. Methods: Time-kill kinetics was tested against Staphylococcus aureus (ATCC 25923), methicillin-resistant S. aureus (MRSA) (ATCC 33591), Staphylococcus epidermidis (ATCC 12228), Staphylococcus haemolyticus (ATCC 29970), Bacillus oleronius (ATCC 700005), and Propionibacterium acnes (ATCC 6919). Assessments were made after 1 min, 5 min, 15 min and 30 min of exposure. At each time point, bacteria were serially diluted, plated, incubated at 37°C overnight, and enumerated. Results: On examination the patient had a visually significant degree of corneal pannus extending centrally in her right eye; conjunctival hyperemia, 3+ papillary reaction, telangiectatic vessels along tarsal margins, sleeves surrounding the lash follicles and debris on the lids and lashes of both eyes. Following a regimen with AVENOVA, there was a dramatic improvement in degree of conjunctival hyperemia as well as the amount of debris and cylindrical sleeves seen around the patient’s lashes. This was achieved without the need for topical or oral antibiotics or anti-parasitic agents. Treatment with AVENOVATM resulted in complete kill (> 99.9%) of S. aureus, S. epidermidis, S. haemolyticus, B. oleronius, and P. acnes in < 1 min. Conclusion: A pure 0.01% hypochlorous acid cleanser, without sodium hypochlorite impurities, hygiene regimen may be of benefit in managing patients with blepharitis. Further prospective clinical studies are warranted. Disclosure: E

ABSTRACTS

- 25 -

Dry Eye Profiles in Patients with a Positive Elevated Surface Matrix Metallopeptidase 9 Point of Care Test versus Negative Patients

V.S. Chang1, N.L. Lanza1,2, F. Valenzuela1, V.L. Perez1, A. Galor1,2 1Bascom Palmer Eye Institute, University of Miami, Miami, FL; 2Miami Veterans Administration Medical Center, Miami, FL

Purpose: To compare dry eye symptoms and signs in patients who tested positive versus those who tested negative for ocular surface matrix metallopeptidase 9 (MMP-9) using the InflammaDry point of care test (RPS, Tampa, FL). Methods: In this cross-sectional study, individuals with dry eye symptoms, as evidenced by dry eye questionnaire 5 (DEQ5) seen in the Miami Veterans Affairs eye clinic, were given standardized questionnaires to assess dry eye symptoms and ocular and non-ocular pain complaints. Also, a complete evaluation was conducted to measure ocular surface signs of dry eye. MMP-9 testing was performed using the InflammaDry once in each eye, per the manufacturer’s instructions. Our main outcome measure was the comparison of dry eye symptoms and signs in MMP-9 positive versus negative patients. Results: Of 110 patients, 43 (39%) were positive for MMP-9 for InflammaDry testing in either eye. No statistically significant differences in demographics, co-morbidities, psychiatric status, ocular surface symptoms, and signs of dry eye were seen in patients based on MMP-9 status. Conclusions: In our population, there was no difference in dry eye profile in both signs and symptoms between those testing positive versus negative for MMP-9 on the ocular surface. Disclosure: N

ABSTRACTS

- 26 -

Features of Neuropathic Ocular Pain in Dry Eye are Associated with Chronic Comorbid Pain Syndromes (CPS)

H. Batawi1,2, D. Covington2,3, K.T. McManus2,3, B. Seiden2,3, E.R. Felix2,3, J. Kalangara2,3, W. Feuer2,3, D. Patin3, E.R. Martin3, K.D. Sarantopoulos3, R.C. Levitt3, A. Galor1,2 1Bascom Palmer Eye Institute, University of Miami; 2Miami Veterans Administration Medical Center; 3Department of Anesthesiology, Perioperative Medicine and Pain Management, University of Miami Miller School of Medicine, Miami, FL

Purpose: To evaluate whether patients with chronic pain syndromes (CPS) are more likely to report symptoms of neuropathic ocular pain. Methods: Cross sectional study at the Miami VAMC. Patients (n=115) were split into two groups based on the presence of chronic pain conditions. An evaluation was performed to assess ocular pain complaints. Results: The magnitude of all ocular pain symptoms were higher in the CPS group (n=79) compared to the non-CPS group (n=36). Specifically, neuropathic pain symptom inventory total scores (27.73 ± 24.32) and evoked pain sub-scores (0.32 ± 0.31) were higher in the CPS group compared to the non-CPS group (18.69 ±18.38, P = 0.052), and (0.21 ± 0.21, P = 0.031), respectively. Conclusion: Patients with multiple CPS have more frequent and severe symptoms of neuropathic ocular pain. Disclosure: N

ABSTRACTS

- 27 -

Low-Dose Topical Preservative-Free Dexamethasone 0.01% and 0.05% for Treatment of Chronic Ocular Surface Disease Unresponsive to Commercially Available Steroids, Antibiotics, and Anti-Allergy Agents

A. Mallick, F. Chin, C. Shih, I. Udell, A. Steiner Hofstra-North Shore-LIJ School of Medicine, Department of Ophthalmology, Manhasset, NY

Purpose: To evaluate the short-term safety and efficacy of topical preservative-free dexamethasone 0.01% and 0.05% for the treatment of ocular surface disease and/or tearing refractory to conventional treatments. Patients’ diagnoses included dry eye syndrome, blepharitis, rosacea, meibomian gland dysfunction, graft versus host disease, Sjogren’s Syndrome, Steven-Johnson Syndrome, allergic conjunctivitis, superior limbic keratoconjunctivitis, and limbal stem cell deficiency. Methods: Retrospective chart review of patients who received topical preservative-free dexamethasone 0.01% and 0.05% (Leiter’s Pharmacy, San Jose, CA) from 9/2011 to 1/2015. Follow-up visits were reviewed for subjective responses to the formulation, development of visually significant cataract, and intraocular pressure (IOP). Responses were graded as moderate/complete resolution of symptoms (50%–100% improvement), mild improvement (25%–50% improvement), or no improvement. Results: One-hundred-twenty-two eyes of sixty-one patients received topical preservative-free dexamethasone for the treatment of ocular surface disease. Of these patients, 55 received 0.01% and 6 patients received 0.05% formulations. Follow up ranged from 1 to 49 months. Forty-four patients (72%) reported moderate or complete resolution of ocular symptoms. Eleven patients (18%) had mild improvement in their symptoms. Six patients (10%) had no change in ocular symptoms. Three patients in our series developed an elevation of intraocular pressure greater than 5 mm Hg above baseline intraocular pressure. Of these patients, two were initially given 0.05% with subsequent reduction of IOP when switched to 0.01%. One patient developed IOP elevation on 0.01%, however had a history of end stage glaucoma. One patient in our series developed progression of cataract requiring surgery. Of the twenty-nine patients previously treated with commercially available steroids (with preservative), twenty-two patients (76%) reported moderate or complete resolution of symptoms, six patients mild improvement (21%), and one patient (3%) reported no improvement with use of topical preservative-free dexamethasone. Conclusions: Topical preservative-free dexamethasone 0.01% and 0.05% could be an effective therapy for recalcitrant chronic ocular surface disease. Minimal risk exists of IOP elevation or formation of visually significant cataract. Disclosure: N

ABSTRACTS

- 28 -

Reduced Efficacy of Low-dose Topical Steroids in Dry Eye Disease Associated with Ocular GVHD

A. Kheirkhah, T. Dohlman, U. Saboo, R. Dana.

Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, MA

Purpose: To determine whether the response of dry eye disease (DED) to low-dose topical steroids is similar between patients with and without ocular graft-versus-host-disease (GVHD). Methods: This study included patients with moderate to severe DED with and without associated ocular GVHD. All cases had an Ocular Surface Disease Index (OSDI) score >22 and corneal fluorescein staining of 4 or more (National Eye Institute grading scale, 0-15). Both GVHD and non-GVHD groups received either a topical steroid (loteprednol etabonate 0.5%) or artificial tear (AT) twice daily for 4 weeks. Clinical signs and symptoms were compared among the subgroups before and after the treatment. Results: 42 patients with DED completed the 4-week follow-up. These included 21 patients with ocular GVHD (including 9 on AT and 12 on steroid) and 21 patients without ocular GVHD (including 11 on AT and 10 on steroid). There were no significant differences among the subgroups at baseline. After 4 weeks of treatment in the non-GVHD group, corneal fluorescein staining decreased significantly in both the AT and steroid treated subgroups (29.8 ± 34.8% and 41.2 ± 36.5%, respectively); however, a significant improvement of OSDI was noticed only in the steroid group (35.1±14.4% reduction). In the GVHD group, there was no significant improvement in OSDI or any clinical signs after treatment with either AT or steroids. Conclusions: Even with similar clinical severity of DED, patients with ocular GVHD have a less favorable response to low-dose topical steroid therapy compared to those without ocular GVHD. These data suggest that a more aggressive therapy may be recommended in these cases. Disclosure: N Support: Bausch & Lomb, Inc.

THYGESON LECTURER

- 29 -

TITLE DATE

Dedication to Dr. Phillips Thygeson Business Meeting 10/30/82

Dan Jones, MD “Emerging Antibiotic Resistance in Ocular Infections: Real and Relative.”

10/28/95

Robert Hendricks, PhD “Cell Regulation of Herpes Simplex Virus-Induced Corneal Inflammation”

10/26/96

Gilbert Smolin, MD "Ocular Allergy" 10/25/97

Richard J. O'Callaghan, PhD "The Role of Bacterial Exoproteins in Experimental Staphylococcus and Pseudomonas Keratitis"

11/7/98

Panel Vancomycin Prophylaxis Mini-symposium 10/23/99

Jerry Niederkorn, PhD "New insights into the Mechanism or Corneal Graft Rejection"

10/21/00

Jules Baum, MD "Amniotic Membrane Transplantation - Is it Effective?" 11/10/01

Gregory Schultze, PhD "Molecular Approaches in the Treatment of Ulcerative Keratitis"

10/19/02

Richard Forster, MD "The Correlation of Microbiology and Pathology in Experimental Endophthalmitis as a Prelude to Focused Therapy"

11/15/03

Linda Hazlett, PhD "Pseudomonas aeruginosa: Models and Treatment of the Disease"

10/23/04

Deborah Langston, MD "Herpes Zoster Neurotrophic Keratopathy" 10/15/05

William T. Driebe, Jr., MD "Contact Lens Related Ulcerative Keratitis" 11/10/06

Sally Atherton, PhD "Herpes Simplex Virus Infections: From Outside In?"

11/09/07

Y. Jerold Gordon, MD "The Life and Times of Adenovirus 1899 - 2008" 11/07/08

Todd P Margolis, MD, PhD "The Establishment of Latent Infection with Herpes Simplex Virus"

10/23/09

Thomas Liesegang, MD "The Varicella Zoster Virus - Translating research in other medical fields to Ophthalmology"

10/15/10

Suzanne M. Fleiszig, OD, PhD "Pseudomonas Aeruginosa Versus Ocular Surface: Who Wins and Why?"

10/21/11

THYGESON LECTURER

- 30 -

(continued) TITLE DATE

John E. Sutphin, Jr., MD “Confocal Microscopy and the Cornea” 11/9/12

Michael Gilmore, PhD “Understanding Epidemic Bacterial Conjunctivitis through Comparative Genomics”

11/15/13

Reza Dana, MD, MSc, MPH “What Have We Learned About Alloimmunity and Autoimmunity From Experimental Cornea Models?”

10/17/14

Eric Pearlman, PhD “New Insights Into the Pathogenesis of Fungal Keratitis: 11/13/15

HARRY HIRSCH LEITER AWARD RECIPIENTS

- 31 -

AWARDEES TITLES YEAR

Robert Snyder, MD, PhD "Increased Risk of Endophthalmitis in Clear Cornea

Cataract Surgery" 2002

Kevin Miller, MD "Do Flies Transmit Trachoma?" 2003

Shinichiro Kobayakawa, MD, PhD "Biofilm Formation by E. faecalis on Intraocular Lens

Material" 2004

Mary Marquart, PhD "Topical Cholesterol as an Effective Treatment for

Pneumococcal Keratitis" 2005

Christine Toutain-Kidd, MD "A Common Additive to Eyedrops, Polysorbate 80,

Inhibits Biofilm Formation of Pseudomonas aeruginosa"

2006

Agnieszka Nagpal, MD "Fusarium and Acanthamoeba Keratitis: Can a Single

Center Detect Outbreaks?" 2007

Alfonso Iovieno, MD "Endosymbionts as Co-Pathogens in Acanthamoeba

Keratitis" 2008

B.H. Jeng, MD "Epidemiology of Ulcerative Keratitis in Northern

California" 2009

Nisha R. Acharya, MD "Topical Fluoroquinolone Use as a Risk Factor for in

vitro Fluoroquinolone Resistance in Ocular Cultures" 2010

Russell N. Van Gelder, MD "Application of Biome Representational in silico

Karyotyping to Characterization of the Contact Lens Microbiome"

2011

Irmgard Behlau, MD “Boston Keratoprosthesis-Associated Endophthalmitis:

Global Incidence and Recommendations for Prevention”

2012

Russell Van Gelder, MD “Torque Teno virus Associated with Culture Negative

Endophthalmitis” 2013

Richard A. Eiferman, MD “Put The Preservative In The Bottle, Not In The Eye!” 2014

OMIG offers special thanks and appreciation to Charles and Morton Leiter of Leiters’ Pharmacy for

establishing the Harry Hirsch Leiter recipient of best paper. Open to all presenters, the best paper is

chosen by the OMIG Board during the business luncheon, which follows each annual meeting. To

acknowledge this generous honorarium of $500.00, recipients give an encore presentation of their

winning paper the following year.

OCULAR MICROBIOLOGY AND IMMUNOLOGY GROUP

Francis S. Mah, MD Executive Vice-President

Phone: 412-301-3202 Fax: 412-647-5119 ocularmicrobiology@gmail.com

OMIG Business Meeting Ceasars Palace, Genoa Room

November 13, 2015 12:15 PM – 1:30 PM

- AGENDA - 1. AAO/OMIG Joint Symposia 2015 Annual Meeting,

Tuesday, November 17, 2015 8:30 – 10:15 AM Venetian Ballroom AB: "Changing Times in the Diagnosis and Management of Ocular Infectious Diseases"

Moderators: Drs. Behlau and Galor Jones/Smolin Lecturer: Todd P Margolis MD PhD 2. AAO 2016 Joint OMIG Symposia: Immunity and the Microbiome: Rethinking How

Ophthalmologist Approach Ocular Infections and Inflammatory Diseases

Moderators: Drs. Galor and Bradley Fouraker 3. Named Lectureship for 2016 AAO/OMIG Joint Symposia

Nominees: Todd Margolis, MD, PhD (2015 Speaker) Kirk Wilhelmus, MD Tom Leitman Alan Carlson, MD Dan Jones Jim Chodosh John Dart Caro Karp

4. Elect New Board Member: Dr. Irmgard Behlau rotating off

a. Eric Romanowski

5. Nominations for OMIG annual meeting Thygeson Award (MD for 2016)

6. Nominations for Executive Vice President (term begins 2017) a. Bennie Jeng b. Emmy Behlau

7. AAO Council Report: Bradley Fouraker 8. Financial Report

a. Educational Grants: Valeant/Bausch & Lomb, TearLab, Leiter’s b. Transfer of tax exempt status from Texas/Baylor/Dr. Jones

9. Annual Meeting Issues: CME, Abstracts, Other

priority of abstracts being accepted for presentation being microbiology and inflammation in the OMIG announcement letter and on the abstract form

at issue is ocular surface neoplasia – diagnosis, pathophysiology, epidemiology, management – medical and surgical, and prognosis

10. New Business

MEMBERSHIP

Membership Roster

New Member 2015 Please send an email with any address changes/corrections to Active Member OcularMicrobiology@gmail.com

Koreishi Aaleya MD 10 Sugarloaf Ct. #202 Baltimore, MD 21209

Richard L Abbott MD

10 Koret Way K 301 San Francisco, CA 94143-0001 E: rabbott@uscf.edu

Nisha Acharya MD

513 Parnassus Ave, S309 San Francisco, CA 94143 P: 415-476-8131 / F: 415-476-0527 E: nisha.acharya@ucsf.edu

Eldad Adler

6208 Waterford Blvd, #106 Oklahoma City, OK 73118 E: eldad1111@yahoo.com

John C Affeldt MD

Loma Linda University 11370 Anderson Street, Suite 1800 Loma Linda, CA 92354

Natalie Afshari MD

Univ of California San Diego Shiley Eye Center 9415 Campus Point Drive, #0946 La Jolla, CA 92093, CA 92093 P: 858-822-1569 / F: 858-822-1514 E: naafshari@ucsd.edu

Mamta Agarwal MD

1560 3rd Street, #706 A San Francisco, CA 94158 P: 415-937-4610 E: drmamta.agarwal@gmail.com

Shruti Aggarwal MD

Dept of Ophthalmology Massachusetts Eye and Ear Infirmary 243 Charles Street Boston, MA 02114 E: shrutiaggarwal_121@yahoo.com

Hoda Ahmadi MD

3226 Albert Ave., Apt. 228 Royal Oak, MI 48073 E: ophtho.badger@gmail.com

Anthony Aldave MD

Jules Stein 100 Stein Plaza, UCLA Los Angeles, CA 90095 E: aldaveejsei@jsei.ucla.edu

Eduardo Alfonso MD

Bascom Palmer Eye Institute 900 NW 17th St. Miami, FL 33101 P: 305-326-6366 E: ealfonso@med.miami.edu

Elias Aliprandis MD

8721 4th Ave Brooklyn, NY 11209-5109 P: / F: (718) 680-1500 E: elias.aliprandis@gmail.com

Guillermo Amescua MD Bascom Palmer Eye Institute 900 NW 17th St Cornea Department Miami, FL 33136 P: 305-326-600 E: gamescua@med.miami.edu

Robert C Arffa MD

1370 Washington Pike Bridgeville, PA 15017 P: 412-206-0335 E: rarffa@verizon.net

Penny A Asbell MD

Mount Sinai Medical Center Dept of Ophthalmology 5th Ave at 100 St. New York, NY 10029 P: 212-241-7977

Amaryllis Avakian MD

R. Luis Coelho, 308 jc 15 CEP 01300009-902 São Paulo, BRAZIL

Richard Awdeh MD

Bascom Palmer Eye Institute 900 NW 17th St. Miami, FL 33101 P: (305) 326-6000 E: rawdeh@med.miami.edu

Uma Badu MD

Rapid Pathogen Screening Inc. 7227 Delainey Court Sarasota, FL 34240 P: 941-556-1857 E: badu@rps-tests.com

Charles Balzli MD

183 Dogwood Circle Brandon, MS 39047 P: 601-941-7995 E: cbalzli@umc.edu

Irina Barequet MD

Sheba Medical Center Goldschleger Eye Institute Tel Hashomer, ISRAEL

Scott D Barnes MD

40 Willow Street Belmont, MA 02478 P: 617-523-7900 / F: 617-573-4300 E: scott_barnes@meei.harvard.edu

Neal P Barney MD

University of Wisconsin 2870 University Ave. Room 206 Madison, WI 53715

Ryan Barrett MD

Cullen Eye Institute 6565 Fannin NC-205 Houston, TX 77030

Gary P Barth MD 2523 Rim Rock Way Santa Rosa, CA 95404

Hatim Batawi MD

Research Fellow Bascom Palmer Eye Institute E: hib5@med.miami.edu

Jules L Baum MD

795 Columbus Ave, Apt. 12B New York, NY 10025 E: julesbaum@icloud.com

Richard F Beatty MD

6101 Pine Ridge Rd Naples, FL 34119

Walter E Beebe MD

10740 N Central Expy, #350 Dallas, TX 75231 E: wbeebe4704@aol.com

Irmgard Behlau MD

Tufts University School of Medicine 136 Harrison Avenue Boston, MA 02111 P: 617-636-6750 E: Irmgard.Behlau@tufts.edu

Rubens Belfort MD

Univ. Fed. Sao Paulo São Paulo 4023062 BRAZIL

Michael W Belin MD

4232 West Summer Ranch Pl. Marana, AZ 85658-4741 P: 518-415-0823 E: mwbelin@aol.com

Marcel Belloso MD

7300 Brompton St., Apt. 5314 Houston, TX 77025-2154 P: 713-991-9369 / F: 713-991-9638 E: marcel@beansa.org

Gregg J Berdy MD

12990 Manchester Rd. Suite 200 Des Peres, MO 63130 P: 314-993-5000 E: gjberdy@charter.net

Neil Berkeley MD

MPEX Pharmaceuticals 11535 Sorrento Valley Rd San Diego, CA 92121

Perry Binder MD

2500 6th Ave. #307 San Diego, CA 92103 P: 858-922-8699 E: garrett23@aol.com

Paulo Jose M Bispo MD

16919 North Bay Road, Apt. 519 Sunny Isles Beach, FL 33160

Membership Roster

New Member 2015 Please send an email with any address changes/corrections to Active Member OcularMicrobiology@gmail.com

Joseph Blondeau MD Royal University Hospital Department of Clinical Microbiology 103 Hospital Ave. Saskatoon, Saskathewan, S7N 0W8 CANADA

Marc A Bodenheimer MD

2020 Kay Street Knoxville, TN 37920-1625 E: bodenm@pol.net

George M Bohigian MD

12290 Manchester Road, Suite 202 St. Louis, MO 63131 P: 314-569-1155 E: bohigian@att.net

Vivien Boniuk MD

40 West 15th Street, #3A New York, NY 10011 P: 212-645-1206 E: boniukv@nychhc.org

Kraig S Bower MD

10753 Falls Road, Pavilion II, Suite 455 Lutherville, MD 21093

Naci Bozkin MD

90 Jackson Pike Gallipolis, OH 45631

Richard Braunstein MD

210 E 64th Street New York, NY 10065 E: rbraunstein@nshs.edu

D. C. Brick MD

6422 E. Speedway Blvd., Ste. 100 Tucson, AZ 85710 P: 520-325-9400 / F: 520-325-8965 E: dcbcornea@aol.com

Brett D Brimhall MD

1626 N. Country Club Dr. Meza, AZ 85201

Jill Brody MD

505 E. Grant St. # 206 Macomb, IL 61455 P: 309-836-3937 E: jbrody@macomb.com

Kimberly Brothers PhD

Eye and Ear Institute, Room 1020 203 Lothrop Street Pittsburgh, PA 15213 E: brothersk@upmc.edu

Michael Brubaker

6817 Vista Ridge Drive, W. Fort Worth, TX 76132

Beau Bryan MD

1203 Woodhollow Drive Temple, TX 76502 E: bbryan@sw.org

Frank Bucci MD Bucci Cataract & Laser Vision Inst. 158 Wilkes-Barr Tsp. Blvd, Suite 201 Wilkes-Barr, PA 18702

Diem Bui MD

Cullen Eye Institute 6565 Fannin NC-205 Houston, TX 77030

John Bullock MD, MPH, Msc

1475 Ridge Gate Road, Unit B Kettering, OH 45429

Terry E Burris MD

Northwest Corneal Services 6950 SW Hampton, Suite 150 Portland, OR 97223 P: 503-624-4814 E: tburris@ifriendly.com

Salim Butrus MD

650 Pennsylvania Ave SE #270 Washington, DC 20003

Armando Caballero PhD

Univ. Mississippi Medical Center Department of Micriobiology 2500 N. State St. Jackson, MS 39216

Michelle Callegan, PhD

Department of Ophthalmology Univ of Oklahoma Health Sciences Center 608 Stanton L. Young Blvd, DMEI PA-418 Oklahoma City, OK 73104 P: 405-271-3674 / F: 405-271-4709 E: michelle-callegan@ouhsc.edu

Joseph Captirotti MD

1400 NE Miami Gardens Drive, Suite 203 N Miami Beach, FL 33179 E: joseph_capriotti@yahoo.com

H. Dwight Cavanagh MD

Univ. Texas Southwestern Med. Ctr Dept. Ophthalmology 5323 Harry Hines Blvd Dallas, TX 75235-9057 P: 214-648-8074 / F: 214-648-2382 E: dwight.cavanagh@utsouthwestern.edu

Patrick Chan MD

1951 W 26th Street, #209 Cleveland, OH 443109-1998 E: draeden@gmail.com

Annie Chan MD

Univ of Oklahoma Health Science Center Dept. of Ophthalmology Dean McGee Eye Institute 608 Staton L. Young Blvd Oklahoma City, OK 73104 E: aychan80@gmail.com

Toby Chan MD

University of Western Ontario 22 Picton Street, Apt. 1206 London Ontario, N6B 3R5 CANADA P: 5199338028 / F: 5196466313 E: tchan86@uwo.ca

Matilda F Chan PhD

Francis I. Proctor Foundation University of California 95 Kirkham St. San Francisco,, CA 94143-0944

Elsie Chan MD

Royal Victorian Hospital 32 Gisborne Street East Melbourne, VIC 03002 AUSTRALIA E: elsiec@med.usyd.edu.au

Naveen Chandra MD

Kaiser Permanente Dept. Ophthalmology 200 Muir Rd. Martinez, CA 94553

Min Chang MD

5058 Villa Crest Nashville, TN 37220

Victoria Chang MD

Bascom Palmer Eye Institute 900 NW 17th Street Miami, FL 33136 E: vchang@med.miami.edu

Steven S Ching MD

Univ. of Rochester Dept. of Ophthalmology 601 Elmwood Ave, Box 659 Rochester, NY 14642 E: steven_ching@urmc.rochester.edu

Chareenun Chirapapaisan MD

Cornea Service Mass Eye & Ear Infirmary 243 Charles Street Boston, MA 02114 E: chareenun_Chirapapaisan@meei.harvard.edu

James Chodosh MD

Mass Eye & Ear Infirmary Home Laboratory 243 Charles St. Boston, MA 02114 E: james_chodosh@meei.harvard.edu

Sing-Pey Chow MD

309/38 Bank Street South Melbourne Victoria, 03205 AUSTRALIA

Jae Lim Chung MD

Kim's Eye Hospital 156 4GA Yeongdeungpo-dong Yeongdeungpo-gu Seoul, 150034 KOREA P: 82-2-2639-7811 / F: 82-2-2633-3976 E: jlchung@kimeye.com

Moonyoung S Chung MD

407 W. Wackerly Street Midland, MI 48640-4719 E: chungmattichak@hotmail.com

Membership Roster

New Member 2015 Please send an email with any address changes/corrections to Active Member OcularMicrobiology@gmail.com

Frank Cignetti MD 2571 Mosside Blvd. Monroeville, PA 15146-3510 E: esoa@pitt.edu

Elisabeth Cohen MD

33 East 70 Street, Apt 6D New York, NY 10021 E: elisabeth.cohen@nyumc.org

Michael Connors PhD

The Ophthalmic Center 8 Technology Drive, Suite 107 East Setauket, NY 11733 P: 631-751-2020 / F: 631-751-0048 E: mceyemd@yahoo.com

Robert A Copeland, Jr. MD

Howard University Hospital Dept. of Ophthalmology 2041 Georgia Ave, NW Washington, DC 20060 E: racopeland@howard.edu

Maria Soledad Cortina MD

University of Illinois Eye & Ear Infirmary Dept of Ophthalmology/ Visual Sciences 1855 W Taylor St. Suite 3.164 Chicago, IL 60612 E: mcortina@uic.edu

John W Cowden MD

Univ. of Missouri-Columbia Dept. of Ophthalmology 1 Hospital Drive Columbia, MO 65212

Julie Crider PhD

PO Box 1634 El Campo, TX 77437 P: 214-796-7930 E: jycrider@collaborativemedicalwriting.com

Andrea Cruzat MD

Mass Eye & Ear Infirmary Dept of Ophthalmology 234 Charles St Boston, MA 02114 P: 617-7107458 E: andrea_cruzat@meei.harvard.edu

Emmett Cunningham, Jr. PhD, MPH

195 Rizal Drive Hillsborough, CA 94010

Tadeu Cvintal MD

R. Maria Figeiredo 283 Sao Paulo, 4002-001 BRAZIL E: iotc@iotc.com.br

Cyril Dalmon MD

3211 Alber Spring Court Lake Oswego, OR 97034-6759 P: 415-307-8340

Reza Dana MD, MSc, MPH Harvard Medical School Mass Eye & Ear Infirmary Cornea Service, 243 Charles St. Boston, MA 02114 P: 617-912-7404 / F: 617-912-0117 E: Reza_Dana@meei.harvard.edu

Mark D Daniel MD

Level 1, 55 Victoria Parade Victoria, 03065 AUSTRALIA

Sujata Das MS L.V. Prasad Eye Institute Patia, Bhubaneswar-751024 INDIA P: 9-1-674-398-7999 / F: 9-1-674-398-7130 E: sujata_das@yahoo.com

Mohammad H Dastjerdi MD

University of Kansas KU Eye Center 7400 State Line Road Prairie Village, KS 66208 P: 913-588-6605 / F: 913-588-0888 E: mdastjer@gmail.com.

Harry Davis MD

Product Manager, Allegan 2525 Dupont Drive Irvine, CA 92612-1599

Michael Davis MD

Rush University Medical Center Department of Ophthalmology 1725 W Harrison St. Suite 945 Chicago, IL 60657 P: 312-622-2653 / F: 312-942-3969 E: mjdavis328@gmail.com

Denise de Freitas MD

Rua Onze de Junho, 977 (Apto) CEP 04041-053 São Paulo-, SP BRAZIL

Robert D Deitch, Jr. MD

200 West 103rd St. Indianapolis, IN 46290 P: 317-817-1733 E: rdeitchjr@aol.com

David Demartini MD

122 La Casa Via, Ste. 221 Walnut Creek, CA 94598 E: drdemartini2000@yahoo.com

Richard F Dennis MD

1725 W Harrison Street, Suite 928 Chicago, IL 60612-3845 E: rdennis@chicagocornea.com

Deepinder Dhaliwal MD

UPMC Eye Center 203 Lothrop St., Suite 800 Pittsburgh, PA 15213 P: 412-647-2214 / F: 412-647-5119 E: dhaliwaldk@upmc.edu

Antonio Di zazzo MD Schepens Eye Research Institute Massachusetts Eye and Ear Infirmary Department of Ophthalmology Harvard Medical School 20 Staniford Street Boston, MA 02114 E: Antonio_DiZazzo@meei.harvard.edu

Jonathan Diamont MD

3700 Vaca Valley Parkway Vacaville, CA 95688

Victor M Diaz-Bonnet MD

269 Pinero Ave. Rio Piedras, PR 00927 P: 809-765-9470 E: hydeparkoph@aol.com

Anil Diwan MD

135 Wood Street West Haven, CT 06516 P: 203-606-9180 / F: 203-937-6137 E: adiwan@mac.com

Lena Dixit MD

Cullen Eye Institute 6565 Fannin NC-205 Houston, TX 77030

Ali Djalilian MD

1855 W. Taylor Street, Suite 3.164 Chicago, IL 60612-7242

Emilio Dodds MD

Montevideo 1410 Buenos Aires ARGENTINA P: 5411-4815-5356 E: emdodds@gmail.com

Claes Dohlman MD

243 Charles Street Boston, MA 02114 P: 617-573-3240 E: claes_dohlman@meei.harvard.edu

Tim D Donald

6900 Grove Rd. Thorofare, NJ 08086

Eric D Donnenfeld MD

2000 N. Village Ave. Rockville Centre, NY 11570 E: ericdonnenfeld@gmail.com.

Donald J Doughman MD

Dept of Ophthalmology Box 493, Mayo Memorial Bldg. Minneapolis, MN 55455

William T Driebe, Jr. MD

Dept of Ophthalmology 1600 SW Archer Road PO Box 100284 Gainesville, FL 32610 P: 352-331-6183 E: bdriebe@eye.ufl.edu

Membership Roster

New Member 2015 Please send an email with any address changes/corrections to Active Member OcularMicrobiology@gmail.com

Katherine Duncan MD University of Maryland School of Medicine 419 W Redwood Street, Suite 470 Baltimore, MD 21201 E: kduncan@umm.edu

Steven P Dunn MD

29201 Telegraph Rd. #101 Southfield, MI 48034 P: 248-350-1130 / F: 248-350-2709 E: stevenpdunn@ameritech.net

Marlene Durand MD

Infectious Disease Associates Massachusetts General Hospital, Cox 5 55 Fruit Street Boston, MA 02114 P: 617-573-3723 / F: 617-726-7653 E: mdurand@partners.org

Lindsey Ebke PhD

Shire Pharmaceuticals 300 Lexington Way Lexington, MA 02421 E: lebke-c@shire.com

Sean Edelstein MD

1755 S Grand Blvd. St. Louis, MO 63104 P: 314-256-3226 E: sedelste@slu.edu

Anthony Eglezos PhD, MBA

75 Commercial Road Melbourne, Victoria 3004 AUSTRALIA E: tony.eglezos@starpharma.com

Richard A Eiferman MD

6400 Dutchman's Pkwy, Suite 220 Louisville, KY 40205 P: 502-895-4200 / F: 502-855-0819 E: reiferman@cs.com

Marilyn Ekins MD

425 St. Mary Ave. Winnipeg, Manitoba, R3C 0N2 CANADA

Randy Epstein MD

Chicago Cornea Consultants, LTD. 806 Central Ave., Suite 300 Highland Park, IL 60035 P: 847-432-6010 E: www.chicagocornea.com

Robert S Feder MD

645 N. Michigan Ave., Suite 440 Chicago, IL 60611 E: r-feder@northwestern.edu

Merle Fernandes MS

LV Prasad Eye Institute Hanumanthawaka Junction Visakhapatnam, Andhra Pradesh 530040 INDIA E: merle@lvpei.org

Jennifer Fernandez MD

575 Anton Blvd. #202 Costa Mesa, CA 92626 P: 714-427-3617 / F: 714-427-3629 E: fernandez_jennifer@pacific-com.com

Linda Ficker MD 22 Bigwood Rd. London, NW11 7BD ENGLAND

Robert Fintelmann MD

332 W Wilshire Drive Phoenix, AZ 85003 E: rofint@gmail.com

Suzi Fleiszig OD, PhD

University of California, Berkeley School of Optometry 688 Minor Hall Berkeley, CA 94705 P: 510-643-0990 / F: 510-642-5109 E: fleiszig@berkeley.edu

George J Florakis MD

Columbia Presbyterian Med. Ctr. 635 W. 165th Street, Suite 303 New York, NY 10032 P: 212-927-2394 / F: 212-781-1188 E: gif2@columbia.edu

Jerry Ford MD

2040 Fleishmann Rd. Tallahassee, FL 32308

Richard K Forster MD

Bascom Palmer Eye Institute 7101 Fairway Drive Palm Beach Gardens, FL 33418 P: 561-515-+1544 E: ncangey@med.miami.edu

S. Lance Forstot MD

8381 South Park Lane Littleton, CO 80120 P: 303-730-0404 / F: 303-730-6163 E: sl4stot@aol.com

Gary N Foulks MD

301 E. Muhammed Ali Blvd. Louisville, KY 40202 P: 502-852-6150 / F: 502-852-4102 E: gnfoul01@louisville.edu

Bradley Fouraker MD

4905 Bayway Place Tampa, FL 33629 P: 813-681-1122 / F: 813-684-4924 E: bfouraker@verizon.net

W. Craig Fowler MD

Dept of Ophthalmology 5154 Bioinformatics Bldg Campus Box 7040 Chapel Hill, NC 27599-7040 P: 919-843-0295 E: cfowler@med.unc.edu

George Frangieh MD

158 Bay Colony Drive Westwood, MA 02090

Juliana Freitas MD

840 Walnut St., Suite 920 Philadelphia, PA 19107 E: jbisco@uol.com.br

Noel Frierson MD Northwest University 645 N Michigan Ave., Suite 440 Chicago, IL 60611 P: 312-503-9271 / F: 312-503-8152 E: n-frierson@northwestern.edu

Joseph Frucht-Pery MD

Hadassah University Hospital PO Box 12000 Jerusalem, il-91120 ISRAEL

Selana Fu MD

6565 Fannin St. Houston, TX 77030

Samuel Fulcher MD

2401 S. 31st ST. Temple, TX 76508

Anat Galor MD

3097 Ohio Street Miami, FL 33133 P: 303-450-6050 E: agalor@med.miami.edu

Richard Garber

Alcon Research, Ltd. 6201 South Freeway Fort Worth, TX 76134 P: 817-551-6937 / F: 817-615-3370 E: richard.garber@alconlabs.com

Kathryn M Gardner MD

242 26th Street Santa Monica, CA 90402

Suzanne Gardner MD

4765 Woodvale Dr. Atlanta, GA 30327

Prashant Garg MD

L.V. Prasad Eye Institute Road No. 2 Banjara Hills Hyderabad, 500034 INDIA P: 91 (4035) 4826-7 / F: 91 (4035) 4827-1 E: prashant@lvpei.org

Robert Garoon MD

Cullen Eye Institute 6565 Fannin NC-205 Houston, TX 77030 P: 713-798-3245 E: robertgaroon@bcm.edu

Bruce D Gaynor MD

Proctor Foundation 513 Parnassus Avenue San Francisco, CA 94122 E: Bruce.Gaynor@ucsf.edu

Michael Gilmore MD

22 Garden Street Boston, MA 02114 E: michael_gilmore@meei.harvard.edu

William Godfrey MD

7400 State Line Road Prairie Village, KS 66208 P: 913-588-6605 / F: 913-588-0888 E: wgodfrey@kumc.edu

Membership Roster

New Member 2015 Please send an email with any address changes/corrections to Active Member OcularMicrobiology@gmail.com

Marc A Goldberg MD The Eye Institute 2000 S. Wheeling Ave., Ste 1010 Tulsa, OK 74104 P: 918-584-4433 / F: 918-584-4479 E: mgoldberg@eyeinst.com

Roger A Goldberg MD Bascom Palmer Eye Institute 900 NW 17th St. - 2nd FL Miami, FL 33136 E: rgoldberg@med.miami.edu

David Goldblum MD

University Eye Clinic Mittlere Str. 91 Basel, 04031 SWITZERLAND E: goldblum@yahoo.com

Michael Goldstein MD

New England Eye Center 750 Washington St. Boston, MA 02111 P: 212-371-6209 / F: 212-371-6209 E: mgvisionny@aol.com

Jeffrey Golen

45 Johnstone Dr., Apt 103 San Francisco, CA 94131 E: golenj@gmail.com

John A Gonzales MD

Francis I. Proctor Foundation 95 Kirkham Street San Francisco, CA 94143 E: john.gonzales@ucsf.edu

John D Gottsch MD

The John Hopkins Hospital The Wilmer Ophthalmological Institute 600 N Wolfe St Baltimore, MD 21287

Aaron Green

Alcon 6201 S Freway Ft. Worth, TX 76134 E: aaron.green@alconlabs.com

Jonathan Greene MD

4 Stagecoach Road Rolling Hills Estates, CA 90274 E: greenej@vision.ucsf.edu

Charlene M Grice MD

1101 Clarity Road Mt. Pleasant, SC 29464 E: grice1@comcast.net

Neil Griffin MD

2170 Midland Rd. Southern Pines, NC 28397

Lewis R Groden MD

USF Eye Institute 12901 Bruce B. Bowns, MDC 21 Tampa, FL 33612 E: lgroden@aol.com

Erich B Groos, Jr. MD Cornea Consultants of Nashville 2400 Patterson St. Ste 201 Nashville, TN 37203 P: (615) 320-7200 E: egroos@gmail.com

Jose L Guell MD

Oceano Glkacial 15 San Cugat Del Valles Barcelona, 8190 SPAIN

Pankaj Gupta MD

University Hospitals Eye Institute University Hospitals Case Medical Center 11100 Euclid Avenue Cleveland, OH 44106 E: gupta93@yahoo.com

Deanine G Halliman PhD

1163 Stephenson Road Stone Mountain, GA 30087 P: 678-464-6950 E: deanine@gmail.com

Stephen M Hamilton MD

3225 Cumberland Blvd, Ste 900 Atlanta, GA 30309

Mark E Hammer MD

2522 W. Jetton Ave. Tampa, FL 33629 P: 813-875-6373 E: hammermd@ix.netcom.com

Kristin Hammersmith MD

840 Walnut St., Suite 920 Philadelphia, PA 19107 P: 215-928-3180 / F: 215-928-3185 E: kristinhammersmith@hotmail.com

Pedram Hamrah MD

Massachusetts Eye and Ear Infirmary Department of Ophthalmology 165 Pleasant St. #109 Cambridge, MA 02139 P: 617-888-3363 / F: 617-573-3011 E: pedram_hamrah@meei.harvard.edu

Sadeer B Hannush MD

400 Middletown Blvd., Suite 110 Langhorne, PA 19047 P: 215-752-8564 / F: 215-752-6968 E: sbhannush@comcast.net

David R Hardten MD

710 E. 24th St., Suite 100 Minneapolis, MN 55404 P: 612-813-3632 / F: 612-813-3658 E: drhardten@mneye.com

Lauren L Harris MD

1286 Island Place East Memphis, TN 38103 E: lharris82@gmail.com

David J Harris, Jr. MD

1928 Alcoa Highway, Suite 324 Knoxville, TN 37920 E: djh2020@aol.com

David J Harris, III, MD Dept of Ophthalmology/Visual Sciences University of Kentucky 740 S. Limestone Lexington, KY 40536 E: david.harris@uky.edu

Hiroshi Hatano MD

Hatano Eye Clinic Lumine Plaza 7F, 438-1 Fujisawa Fujisawa City, 251 JAPAN David G Heidemann MD 29201 Telegraph Rd. #101 Southfield, MI 48034 P: 248-350-1130 / F: 248-350-2709 E: dgheidemann@gmail.com

Ramzi Hemady MD

Univ. Maryland Hospital Dept. Ophthalmology 22 S. Greene St. Baltimore, MD 21201 P: 410-218-1638 E: rhemady@verizon.net

David Hinkle MD

281 Lincoln Street Worcester, MA 01605

Jeffery A Hobden PhD

LSU Health Science Center Dept. of Micro, Immuno & Parasit 1901 Perdido St. New Orleans, LA 70112

Kelly Hodson MD

2201 Jenks Ave. Panama City, FL 32405 P: 850-896-7232 E: kellylaraann@gmail.com

Ana Luisa Hofling-Lima MD

Escoa Paulista De Medicina AV. Ibijau 331 4th Floor Sao Paulo, 04524-020 BRAZIL

Edward J Holland MD

2355 Mohawk Lane Glenview, IL 60025

Gary N Holland MD

Jules Stein Eye Institute 100 Stein Plaza, UCLA Los Angeles, CA 90095-7000 P: 310-825-5440 / F: 310-825-5058 E: holland@jsei.ucla.edu

Wayne Holman MD

Ridgeback Capital 430 Park Avenue 12th Floor New York, NY 10022 P: 212-624-2602 E: kim@ridgebackcap.com

Douglas S Holsclaw MD

Glenview, IL 60025 Hillsborough, CA 94010

Membership Roster

New Member 2015 Please send an email with any address changes/corrections to Active Member OcularMicrobiology@gmail.com

Henry Holt MBBS Lions Eye Institute 1220 New Scotland Road, Suite 102 Slingerlands, NY 12159 E: hncl1983@gmail.com

Andrew Holzman MD

9808 Glynshire Way Potomac, MD 20854-2028

Alice Hong MD

321 E 13th Street, #12 J New York, NY 10003 P: 917-716-3217 E: alice.hong@gmail.com

Hugo Hsu MD

Anheuser-Busch Institute Cornea and External Disease 1755 South Grand Blvd St. Louis, MO 63104 P: 314-256-3227 / F: 314-771-0596 E: hyhsu_2000@yahoo.com

Allen Hu MD

2200 NW 26th Street Owatonna, MN 55060 E: huang.allen@mayo.edu

Steve Hudson CEO

Healthy Environment Innovations, LLC 273 Locust Street, Suite B Dover, NH 03820 E: hgisrh@gmail.com

Judith Hutcheson MD

555 Gateway Dr. Napa, CA 94558

David G Hwang MD

University of California Department of Ophthalmology, K301 San Francisco, CA 94143-0412 P: 415-476-7977 E: David.Hwang@ucsf.edu

Joon Y Hyon MD

Dept of Ophthalmology Seoul National University Bundang Hospital 300 Gumidong Bundang-gu, Seongnam, Gyeonggi 463-707 KOREA E: jyhyon@snu.ac.kr

Alfonso Iovieno MD

Moorsfield Eye Hospital 139 York Way Apt. 7 London, England N79LG GREAT BRITAIN P: 44-077-676-05415 E: alfonsoiovieno@hotmail.com

Edward K Isbey, III MD

8 Medical Park Dr. Asheville, NC 28803

Sandhya Iyer MD

5323 Harry Hines Blvd Dallas, TX 75390-7201 E: siyer17@gmail.com

Bruce H Jackson MD Kentucky Center for Vision PSC 120 North Eagle Creek Lexington, KY 40509

Deborah Jacobs MD

Boston Foundation for Sight 464 Hillside Avenue, Suite 205 Needham, MA 02494 E: djacobs@bostonsight.org

Ronald G Jans MD

#600 - Chinook Prof. Bldg. 6455 McLeod Trail South Calgary, Alberta, T2H 0K9 CANADA E: drjans@janseye.com

Bennie H Jeng MD

Dept of Ophthalmology/Visual Sciences University of Maryland School of Medicine 419 W. Redwood Street, Suite 470 Baltimore, MD 21201 E: BJeng@som.umaryland.edu

Allan D Jensen MD

200 E. 33rd St. #426 Baltimore, MD 21218

Harold Jensen PhD

Allergan Inc. 2525 Dupont Drive T2-4D Irvine, CA 92612-1599

George John MD

6420 Dutchmans Pkwy Suite 220A Louisville, KY 40205

Anthony Johnson MD

3851 Roger Brooke Drive, Bldg 3663 Fort Sam Houston, TX 78234-4501 P: 210-496-7184 / F: 210-916-2946 E: tonyceferinna@hotmail.com

William H Johnston MD

#3-1179 Seafield Crescent Nanaimo, BC, V9S 4S1 CANADA P: 250-753-6960 / F: Fax: 250-753-6930 E: williamj@island.net

Mark E Johnston MD

Nebraska Laser Eye Associates 4909 S 118th St. Omaha, NE 68137 P: 402-397-2010 / F: Fax: 402-397-8439 E: johnston@nebraskaeye.com

Dan B Jones MD

3723 Waycross Lane Frisco, TX 75033 E: dbj9@comcast.net

Minyoung Jung PhD

Taejoon Pharm 657-87 Hannam-dong Yongsan-gu Seoul, 140887 SOUTH KOREA E: myjung@taejoon.co.kr

Carolyn M Kalsow Krause PhD Ocular Research Services PO Box 202 Mendon, NY 14506 P: 585-582-6177 E: ckalsow@att.net

Joanne Kang MD

New York Eye and Ear Infirmary 310 E. 14th Street New York, NY 10003

Douglas Katz MD

1760 Nicolasville Rd, Suite 203 Lexington, KY 40503

Adam H Kaufman MD

University of Cincinnati Med. Ctr. Univ. Med. Arts Bldg ML 665-E 222 Piedmont Ave., Suite 1700 Cincinnati, OH 45219

Jeremy D Keenan MD

95 Kirkham Street San Francisco, CA 94143 E: jeremy.kennan@ucsf.edu

Ahmad Kheirkhah MD

107 Charles Street, Apt. 2 Boston, MA 02114 E: ahmad_kheirkhah@meei.harvard.edu

Daniel Killingsworth MD

One Freedom Way Augusta, GA 30904 P: 706-733-0188 E: dankillingsworth@att.net

Shane K Kim MD

Proctor Foundation, Box 0944 95 Kirkham St. San Francisco, CA 94143-0412

Stella Kim MD

2340 Bolgover Street Houston, TX 77005

Shinichiro Kobayakawa MD

Dept. of Ophthalmology, Toho U 2-10-3 Sannoh, Ohta-ku Tokyo, 1430023 JAPAN P: 81337624151 / F: 81332980030 E: covanet@aol.com

Ellen Koo MD

3233 S Caroline Drive, Apt. 1 Jupiter, FL 33458 E: ellenkoo2020@gmail.com

Regis P Kowalski MS,[M]ASCP

Eye & Ear Institute of Pittsburgh Ophthalmic Microbiology Dept. 203 Lothrop St., 6th Floor Pittsburgh, PA 15213 P: 412-647-7211 E: kowalskirp@upmc.edu

Membership Roster

New Member 2015 Please send an email with any address changes/corrections to Active Member OcularMicrobiology@gmail.com

Rebecca Kuennen MD 915 Olentangy River Road Columbus, OH 43212, OH 43212 E: rebecca.kuennen@osumc.edu

Abha Kumar MD

2724 Ross Rd. Palo Alto, CA 94303

Irene Kuo MD Wilmer Eye Institute Johns Hopkins Univ School of Medicine 4924 Campbell Blvd. #100 Baltimore, MD 21236 E: ickuo@jhmi.edu

Jocelyn Kuryan MD

104-20 Queens Blvd, Apt. 22 H Forest Hills, NY 11375 P: 215-760-4008 E: jocelyn.kuryan@gmail.com

Peter Laibson MD

Wills Eye Hospital 840 Walnut St., Ste. 920 Philadelphia, PA 19107

Marlyn P Langford PhD

Dept. Ophth. LSU Med Center 1501 Kings Hwy. PO Box 33932 Shreveport, LA 71130-3932 P: 318-675-5018 E: mlangf@lsuhsc.edu

Deborah Langston MD

Mass Eye & Ear Infirmary 243 Charles St. Boston, MA 02114 P: 612-573-4041 / F: 617-573-4300 E: drpl@yahoo.com

Jeffrey D Lanier MD

Houston Eye Associates 2855 Gramercy Houston, TX 77025 P: 713-668-6828 E: jdlanier@aol.com

Jonathan H Lass MD

Case Western Reserve University Case Medical Center 11100 Euclid Ave. Cleveland, OH 44106 P: 216-844-8590 E: jonathan.Lass@uhhospitals.org

Noelle Layer MD

1254 5th Avenue San Francisco, CA 94122 E: layern@vision.ucsf.edu

Scott Lee MD

3300 Telegraph Ave Oakland, CA 94609-3028 P: (510) 444-1600

Anna Lehmann

Cullen Eye Institute 6565 Fannin NC-205 Houston, TX 77030

Howard M Leibowitz MD 67 Summer St. Weston, MA 02493

Charles Leiter PharmD

1700 Park Ave. #30 San Jose, CA 95126 P: 408-292-6772 / F: 408-292-7754 E: cleiter@leiterrx.com

Richard G Lembach MD

OSU Eye Physicians & Surgeons 456 W. 10th Ave., Room 5241 Columbua, OH 43210 P: 614-293-8126

Seba Leoni MD

6201 S. Freeway Ft. Worth, TX 76134

David Liang MD

Penn State College of Medicine 500 University Drive MC HU19 Hershey, PA 17033-0850 P: (717) 531-5690 / F: (717) 531-5009 E: dliang@hmc.psu.edu

Henia Lichter MD

19 Haodem St. Hod-Hasaron 45350 ISRAEL

Thomas J Liesegang MD

24517 Deer Trace Drive Ponte Vedra, FL 32082 P: 904-285-1600 E: tliesegang@mayo.edu

Thomas Lietman MD

UCSF-Proctor Foundation 145 Sutro Heights San Francisco, CA 94121 P: 415-502-2662 / F: 415-476-0527 E: tom.lietman@ucsf.edu

Lyndell Lim MD

Centre for Eye Research-Australia 32 Gisborne St. East Melbourne VIC, 3002 AUSTRALIA

Charles Lin MD

2452 Watson Ct Palo Alto, CA 94303 E: lincc@stanford.edu

Thomas D Lindquist MD, PhD

Bellevue Medical Center 11511 NE 10th St., W370 Bellevue, WA 98004 P: 425-502-3353 E: lindquist.t@ghc.org

Anthony Lombardo MD

8103 Clearvista Pkwy, Suite 136 Indianapolis, IN 46256 E: anthlombardo@yahoo.com

Marta Lopatynsky MD

261 James St., Suite #2D Morristown, NJ 07560 E: molopat@aol.com

Anthony J Lubniewski MD WUDOVS, 660 S. Euclid Box 8096 St. Louis, MO 63110 P: 314-362-3937 E: lubniewski@vision.wustl.edu

Jodi Luchs MD

2185 Wantagh Ave. Wantagh, NY 11793 P: 516-785-3900 / F: 516-783-0033 E: jluchs@aol.com

Maureen Lundergan MD

6333 Main Street, Suite 1 Williamsville, NY 14221 E: eniles20/20@gmail.com

Charles Mackel MD

Department of Ophthalmology Lahey Clinic 41 Mall Road Burlington, MA 01805

Marian Macsai MD

NorthShore University Health System 1331 Church St. Northbrook, IL 60062 P: 847-714-9116 / F: 847-657-1949 E: pdow@northshore.org

Jorge Maestre MD

University of Miami 1638 NW 10th Ave McKnight, Room 606A Miami, FL 33136 P: 305-547-3694 E: jmaestre@med.miami.edu

Malcolm Magovern MD

7575 Cold Harbor Rd. Suite 2E Mechanicsville, VA 23111 E: cfifer@richmondeye.com

Francis S Mah MD

10666 N. Torrey Pines Road MS 214 La Jolla, CA 09203 P: 858-554-7996 / F: 858-554-6726 E: Mah.Francis@ScrippsHealth.org

Adnan Mallick MD

Department of Ophthalmology Hofstra-North Shore-LIJ School of Med 600 Northern Boulevard, Suite 214 Great Neck, NY 11021 E: adnanm3m3@aim.com

Sid Mandelbaum MD

178 E. 71 St. New York, NY 10021

Richard L Manka MD

63 Otis Avenue St. Paul, MN 55104 P: 612-863-2020

Membership Roster

New Member 2015 Please send an email with any address changes/corrections to Active Member OcularMicrobiology@gmail.com

Mark J Mannis MD 4860 Y St. Suite 2400 Sacramento, CA 95817 P: 916-734-6957 E: mjmannis@ucdavis.edu

Todd Margolis MD, PhD

WUMS CB 8096 660 South Euclid St. Louis, MO 63110 E: margolist@vision.wustl.edu

Maria Carolina Marquezan MD

Dept of Ophthalmology/Visual Sciences Paulista School of Medicine São Paulo Hospital Federal University of São Paulo Av Haiti, 193, apto 1404 Jd das Américas, Cuiabá – MT E: mcmarquezan@hotmail.com

Steven Maskin MD

3001 Swann Ave. Tampa, FL 33609 P: 813-875-0000 E: drmaskin@tampabay.rr.com

Rookaya Mather MD

Ivey Eye Institute 268 Grosvenor St London Ontario, N6A 4V2 CANADA P: 519-646-6409 / F: 519-646-6394 E: rookaya.mather@sjnc.london.on.ca

Alice Y Matoba MD

Cullen Eye Institute 6565 Fannin NC-205 Houston, TX 77030 P: 713-798-3245 E: amatoba@bcm.edu

Thomas Mauger MD

Ohio State University OSU Eye and Ear Institute 915 Olentangy River Road Columbus, OH 43212 P: 614-293-5635 E: thomas.mauger@osumc.edu

Clare McCormick MD

University of Mississippi Med. Ctr. Department of Microbiology 5018 Canton Heights Dr. Jackson, MS 39211 E: cmccormick@microbio.umsmed.edu

James P McCulley MD, FACS, FRCOphth

UT Southwestern Medical Center 5323 Harry Hines Boulevard Dallas, TX 75235-9057 P: 214-648-3407 E: james.mcculley@utsouthwestern.edu

Tim McCulley MD

Bascom Palmer Eye Institute 600 N Wolfe St Wilmer 110 Baltimore, MD 21287 E: tmccull5@jhmi.edu

Lester McDonald MD RR 4, Box 47A Benton Rd Dalton, PA 18414

Peter McDonnell MD

Wilmer Eye Institute 600 N. Wolfe Street Baltimore, MD 21287-0005 E: pmcdonn1@jhmi.edu

Mike McLerrey MD

27365 Betarol Mission Viejo, CA 92697

Beeran Meghpara MD

Baylor College of Medicine One Baylor Plaza, NC205 Houston, TX 77030-3411 P: 708-829-8744 / F: 713-798-4364 E: meghpara@bcm.edu

David Meisler MD

Cleveland Clinic 9500 Euclid Ave. Cleveland, OH 44195-5024

John C Merriam MD

Edward S. Harkness Eye Inst. 635 W. 165th Street New York, NY 10032 P: 212-305-5402 / F: 212-781-1188 E: jcm5@columbia.edu

Seth Meskin MD

New York Eye & Ear Infimary 310 E. 14th St. New York, NY 10003

Jay Meyer MD

100 Village Circle way, #1424 Durham, NC 27713 E: jay_meyer@rocketmail.com

Roger F Meyer MD

623 Rivard Blvd. Grosse Pointe, MI 48230

Shazad Mian MD

1000 Wall St. Ann Arbor, MI 48105

Mark Mifflin MD

John Moran Eye Center 50 N. Medical Dr. Salt Lake City, UT 84132

John B Milam MD

1421 North State St., #301 Jackson, MS 39202

Corey A Miller MD

1485 E. 3900 So. #103 Salt Lake City, UT 84124 P: 801-277-1087 E: cmillermd@att.net

Darlene Miller DHSc, MPH University of Miami-School of Medicine Bascom Palmer Eye Institute/ABLEH 900 NW 17th St. Miami, FL 33136 P: 305-326-6034 / F: 305-547-3661 E: d.miller3@umiami.edu

Kevin Miller MD

Jules Stein Eye Institute 100 Stein Plaza, UCLA Los Angeles, CA 90095

Mark Milner MD

2880 Old Dixwell Ave. Hamden, CT 06518 E: milnerms@aol.com

Snigdha Mishra

Alcon Labs 6201 South Freeway Mail Code TC-44 Fort Worth, TX 76134-2099 P: 817-551-4930 / F: 817-615-3831 E: snigdha.mishra@alconlabs.com

Mary Beth Moore MD

1650 Response Rd Sacramento, CA 95815 E: mary.beth.moore@kp.org

Hamilton Moreira MD

Rua Paulo Gorski 1530 Curitiba, 80210-220 BRAZIL

Rodrigo Morizot

Federal University of Sao Paulo Humaita 282 1105 bloco 1 Rio de Janeiro, Brazil 22261-001 E: rodrigomorizot@hotmail.com

Timothy W Morris PhD

Research Fellow Microbiology and Sterilization Sciences Bausch & Lomb, Inc. 1400 N. Goodman Street Rochester, NY 14609 P: (585) 338-5255 E: Timothy.W.Morris@bausch.com

Gene Moss MD

574 Lone Tree Dr Mt. Pleasant, SC 29464-8170

Cristina Muccioli MD

Rua Botucatu 822 São Paulo, 4023062 BRAZIL

Rodrigo Muller MD

10 Emerson Place, 1P2J Boston, MA 2114 E: rodrigo_muller@meei.harvard.edu

Agnieszka Cantre Nagpal MD

Floor 3, Room 3A9 4601 Dale Road Modesto, CA 95356 E: agnescantre@gmail.com

Membership Roster

New Member 2015 Please send an email with any address changes/corrections to Active Member OcularMicrobiology@gmail.com

Takeshi Naito MD Tokushima Univ. Sch. Med. Dept. of Ophthalmology Kuramato-Machi Tokushima, 770-8503 JAPAN

Ron Najafi

NovaBay Pharmaceuticals, Inc. 4000 Civic Center Dr., Suite 210B San Rafael, CA 94903 P: 415-444-0300 / F: 415-444-0301

Kathryn Najafi-Tagal MD

NovaBay Pharmaceuticals, Inc. 4000 Civic Center Dr. Suite 210B San Rafael, CA 94903 P: 415-444-0300 / F: 415-444-0301 E: kn@najafimd.com

Kamal F Nassif MD

2300 North Mayfair Rd. #1155 Milwaukee, WI 53226 P: 414-258-6880 E: knassif@sbcglobal.net

Anthony B Nesburn MD

Hewitt 2026 843 Health Sciences Road Irvine, CA 92697 E: anesburn@uci.edu

Lara Newman MD

Dept of Ophthalmology/Visual Sciences University of Louisville 301 E. Muhammad Ali Boulevard Louisville, KY 40202 E: lrnewman526@gmail.com

Catherine Newton MD

6420 Dutchmans Pkwy #16 Louisville, KY 40205 P: 502-893-1888 / F: 502-893-4446 E: cnewtonmd@aol.com

Duane Y Nii MD

1648 E. Herndon Ave. #101 Fresno, CA 93720

Odd A Nordbo MD

Fjordvelen 1 Oslo, N-0139 NORWAY E: odd_asm.und.nordbo@chello.no

Gary D Novak PhD

Pharma Logic Development 17 Bridgegate Dr. San Rafael, CA 94903-1093

Terrence O'Brien MD

Basom Palmer Eye Institute 7101 Fairway Drive Palm Beach Gardens, FL 33417 P: 561-515-1544 / F: 561-355-8600 E: ncangey@med.miami.edu

William J O'Brien, Jr. PhD

Froedtert & Medical College of Wisconsin 925 N. 87th St. Milwaukee, WI 53226-4812

Richard J O'Callaghan MD Department of Microbiology University of Mississippi Med. Ctr. Jackson, MS 30216 E: rocallaghan@microbio.umsmed.edu

Silvia Odorcic MD, FRCSC

Massachusetts Eye and Ear Infirmary Department of Ophthalmology 243 Charles Street Boston, MA 02114 E: silvia.odorcic@gmail.com

Patrick Oellers MD

3581 E Glencoe St. Apt 104 Miami, FL 33133 P: 954-305-1496 E: poellers@med.miami.edu

Gregory S Ogawa MD

Eye Associates of New Mexico 8801 Horizon Blvd., NE, Suite 360 Albuquerque, NM 87113 P: 505-768-1322 / F: 505-244-9566 E: gogawa@eyenm.com

Takahiro Ogawa PhD

Senju Pharmaceutical Co., Ltd. Clinical Development 2-5-8-Hiranonachi chuuo-ku Osaka, 541-0046 JAPAN

Yukinobu Okajima MD

2-16-7 Konna Minatoku Tokyo, 103-0023 JAPAN

Judy Ou MD

3200 Kearney Street Fremont, CA 94538-2299 E: judyicou@gmail.com

Boris Ovodenko MD

New York Eye and Ear Infirmary Dept. Ophthalmology & Lab Medicine 310 E. 14th St. New York, NY 10030

Geoffrey R Owen PhD

Alcon Research Ltd 6201 South Freeway MS R-1-14 Ft. Worth, TX 76134-2099 P: 817-551-3022 / F: 817-568-6960 E: Geoffrey.Owen@AlconLabs.com

Becky Palchak MD

555 Gateway Dr. Napa, CA 94558

Sotiria Palioura MD, PhD

2555 Collins Ave Apt 805 Miami Beach, FL 33140 E: sotiria.palioura@gmail.com

Gregory Pamel MD

115 E. 61st St. 1B New York, NY 10021 E: gjpny@yahoo.com

Rohit Parihar MD 502 E New Haven Avenue Melbourne, FL 32901

Carolyn Parrish MD

1928 Bristol Ct Brentwood, TN 37027 E: cmparrish80@gmail.com

Stephen Pascucci MD

Coconut Professional Center 23415 Walden Center Drive Bonita Springs, FL 34136 P: 239-949-2021 / F: 239-949-1500 E: sep@bonitaeye.com

Krisna Patel

2931 Oak Street Kansas City, MO 64108 P: 630-457-0138 E: krishnapatel515@gmail.com

Jerry R Paugh OD, PhD

Southern California College of Optometry 2575 Yorba Blvd Fullerton, CA 92831-1699 P: 714-449-7487 / F: 714-992-7809 E: jpaugh@scco.edu

Rhonda Peebles

Vistakon Pharmaceuticals LLC 7500 Centurion Parkway, Suite 100 Jacksonville, FL 32256 E: RPeebl9@its.jnj.com

Victor L Perez MD

900 NW 17th St. Miami, FL 33136 P: 305-326-6302 E: vperez9@med.miami.edu

Henry Perry MD

2000 N Village Ave, Suite 402 Rockville Centre, NY 11570-1001 P: 516-766-2519

Jeff Peterson MD

Baylor College of Medicine 6565 Fannin Street, NC205 Houston, TX 77030

Roswell R Pfister MD

2198 Columbiana Road, Suite 200 Vestavia Hills, AL 35216

Evan Pike MD

8921 North Wood Sage Road Peoria, IL 61615 E: pikefish964@gmail.com

Roberto Pineda MD

40 Pleasant St. Waltham, MA 02452 P: 617-573-4300 E: rpineda@partners.org

Patricia Ple-Plakon MD

3455 Locke Avenue, Suite 220 Fort Worth, TX 76107 E: pleplakon@gmail.com

Membership Roster

New Member 2015 Please send an email with any address changes/corrections to Active Member OcularMicrobiology@gmail.com

Ronald D Plotnik MD 601 Elmwood Ave, Box 659 Rochester, NY 14642

Tisha Prabriputalcoong MD

Ramathibodi Hospital Dept. of Ophthalmology Rama 6 Road, Rajatevi Bangkok 10400, 94143 THAILAND

Jonathan D Primack MD

4 Bobolink Drive Wyomissing, PA 19610 P: 610-378-1344 / F: 610-327-8528 E: jonathanprimack@yahoo.com

Dawn Pruitt MD

4 Bobolink Drive Wyomissing, PA 19610

Yureeda Qazi MD

Massachusetts Eye and Ear Infirmary Department of Ophthalmology 243 Charles Street Boston, MA 02114

Ying Qian MD

30 N Union St., Ste 101 Rochester, NY 14607-1345 P: 216-444-2020 / F: Cell: 215-668-1890

Irving Raber MD

100 Presidential Blvd. Suite 200 Bala Cynwyd, PA 19004 E: raber101@comcast.net

Theodore Rabinovitch MD

2116 Finch Ave. West, Suite 407 Toronto, Ontario, M3N 2V6 CANADA

Aleksandra Rachitskaya MD

170 SE 14th Street, Apt 1507 Miami, FL 33131 E: arachitskaya@med.miami.edu

Michael B Raizman MD

Tufts Univ. School Medicine Dept. Ophthalmology 750 Washington St. Boston, MA 02111 E: mraiz@comcast.net

Leela Raju MD

UPMC Eye Center 203 Lothrop Street, Suite 800 Pittsburgh, PA 15213 E: rajulv@upmc.edu

Fabio Ramos de Souza Carvalho MD

Federal University of Sao Paulo Alberto Nascimento Junior 178, BL 01, Apto. 103 Jd Bonfigliolio Sao Paulo 05595-040 BRAZIL P: 55-11-3731-2271 E: frscarvalho@gmail.com

Gullapalli N Rao MD L.V. Prasad Eye Institute L.V. Prasad Marg Road 2 Banjar Hills Hyderabad, 500-034 INDIA P: 9.1406551037e+011 / F: 9.1402354827e+011

E: gnrao@lvpei.org G. Ashok Kumar Reddy PhD

LV Prasad Eye Institute Jhaveri Microbiology Center Banjara Hills Hyderabad, 500 034 INDIA P: 91-40-30612517512520 / F: 91-40-23548271

E: ashokkumar@lvpei.org Rachel Reem MD

Ohio State University Dept of Ophthalmology 915 Olentangy River Road Columbus, OH 43212 E: rachel.reem@osumc.edu

William J Reinhart MD

10701 East Blvd Cleveland, OH 44106 E: wjreinhart@sbcglobal.net

Michelle Rhee MD

310 East 14th St. New York, NY 10003

Marcus Rhem MD

1515 Lake Lansing, Ste H Lansing, MI 48912

Carolyn Rice MD

Pacific Communications 575 Anton Blvd. Costa Mesa, CA 92626

Mike Rinehart MD

Santen Inc. 555 Gateway Dr. Napa, CA 94558

David C Ritterband MD

Ophthalmic Consultants, PC New York Eye and Ear Infirmary South Bldg., 310 E. Fourteenth St. New York, NY 10003-4201 P: 212-505-6550 / F: 212-979-1772 E: ritterband@msn.com

Lorena Riveroll-Hannush MD

2052 Silverwood Dr. Newton, PA 19840

Melvin I Roat MD

1019 Stanford Dr. Wynnewood, PA 19096 P: 610-645-7643 E: miroatmd@yahoo.com

Calvin M Roberts MD

Weill Medical College of Cornell Univ. 876 Park Avenue New York, NY 10021

Stella M Robertson PhD 7045 Shadow Creek Court Fort Worth, TX 76132 P: 817-991-1230 / F: 817-370-2731 E: robertson.stella.m@gmail.com

Ashley Rohr MD

240 E. Illinois Street, Apt 2210 Chicago, IL 60611 E: ashleyarohr@gmail.com

Eric G Romanowski MS

University of Pittsburgh Eye & Ear Institute, Room 1020 203 Lothrop St. Pittsburgh, PA 15213 P: 412-647-2245 E: romanowskieg@upmc.edu

Jennifer Rose-Nussbaumer, MD

University of California San Francisco Proctor Foundation 513 Parnassus Avenue San Francisco, CA 94122 E: jennifer.rose@ucsf.edu

Steven I Rosenfeld MD

16201 S. Military Tr. Delray Beach, FL 33484 P: 561-498-8100 E: srosenfeld@gmail.com

George Rosenwasser MD

Central Pennsylvania Eye Institute 825 Fishburn Rd. Hershey, PA 17033-3405 P: 717-533-5200 / F: 717-533-26206 E: gr@cpeye.com

Walter M Rotkis MD

1221 Madison, #1420 Seattle, WA 98104 P: (206) 386-2516 E: wrotkis@aol.com

J. James Rowsey MD

124 Sand Dollar Lane Sarasota, FL 34242-1336 E: jrowsey@verizon.net

David Rupp MD

Allergan Inc. 2525 Dupont Dr. Irvine, CA 92612-1599

Jaenne Mah Sadorra MD

840 Walnut St., Suite 920 Philadelphia, PA 19107

Osamah J Saeedi MD

2473 N Field St., Apt. 3042 Dallas, TX 75201 P: 267-977-4658 E: ojsaeedi@hotmail.com

Michael A Saidel MD

Dept. of Ophthalmology & Visual Science 5841 S. Maryland, MC 2114 Chicago, IL 60637

Membership Roster

New Member 2015 Please send an email with any address changes/corrections to Active Member OcularMicrobiology@gmail.com

Carolyn M Sakauye MD 1122 "S" St. Fresno, CA 93721 P: 559-486-5000 / F: 559-439-7854 E: csakauye@emcfresno.com

Rob Sambursky MD

13946 Wood Duck Circle Bradenton, FL 34202 P: 941-727-1510 E: RobSambo@yahoo.com

Mwenda Samda MD

The New York Eye & Ear Infirmary Dept of Pathology and Lab Medicine 310 E. 14th Street New York, NY 10003 P: 212-979-4336 / F: 212-263-5451

John R Samples MD

Casey Eye Institute 3181 SW Sam Jackson Rd. Portland, OR 97201

Christine Sanfilippo PhD

Bausch & Lomb Vision Care 1400 N. Goodman Rochester, NY 14609 E: christine.sanfilippo@bausch.com

Wiwan Sansanayudh MD

209 Sukbothai 10 Dusit Bangkok, 10300 THAILAND E: wiwans@hotmail.com

Carmen Santos MD

269 Pinero Ave. Rio Piedras, PR 00927 P: 809-765-9470 E: csantosdr@gmail.com

P.P.R. Saunders MD

303-6411 Nelson Ave. Burnaby, V5H 4H3 CANADA P: 604-433-1258 / F: 604-433-6154 E: pksaund@shaw.ca

Michael Savetsky MD

2200 Kerwin Road, Apt. 603 Cleveland, OH 44118-3964 P: 516-698-0761 E: darkhaze3@gmail.com

William Sawyer MD

2390 River Run Trace Columbus, OH 43235 P: 817-939-8249 E: willsawyer@yahoo.com

Alan Schaeffer MD

726 Goodman Road E Suite B Southaven, MS 38671 P: (662) 349-1959 E: laserme@aol.com

Scott Schatz PhD

Nova Southeastern University College of Optometry 3200 S. University Dr. Ft. Lauderdale, FL 33328

Barry A Schecter MD 1717 Woolbright Rd. Boynton Beach, FL 33426

Rhett Schiffman MD

Allergan Inc. 2525 Dupont Drive, T2-4D Irvine, CA 92612-1599 P: 714-246-5208 / F: 714-246-4002 E: schiffman_rhett@allergan.com

Barry Schlech PhD

Alcon, Inc. 6201 South Freeway Mail Code R2-29 Ft. Worth, TX 76134

Ivan R Schwab MD

UC Davis Med. Ctr Dept. of Ophthalmology 4860 Y St., Ste 2400 Sacramento, CA 95817 P: 916-734-6071 / F: 916-734-6992 E: irschwab@ucdavis.edu

Tom Schwartz MD

Eye Care Associates of Sarasota 1219 S. East Ave., Suite 105 Sarasota, FL 34239 P: 941-957-4216 / F: 941-954-1835 E: TLS11260@aol.com

Craig See MD

1202 Hickory Run Lane Wildwood, MD 63005 P: 636-484-3815 E: craig.see@gmail.com

John Seedor MD

New York Eye & Ear Infirmary Ophthalmic Consultants, PC 310 E. 14th St. New York, NY 10003 P: 212-505-6550 / F: 212-979-1772 E: jseedor@nyee.edu

Mahendra K. Shah MD

836 49th Street New York, NY 11220-2422 E: aaryanshah2008@yahoo.com

Nabeel Shalabi MD

Bascom Palmer Eye Institute 1638 NW 10th Avenue Miami, FL 33136 E: n.shalabi@med.miami.edu

Robert Shanks MD

University of Pittsburgh 203 Lothrop St. 1020 Eye & Ear Institute Pittsburgh, PA 15213 P: 412-647-3537 / F: 412-647-5880 E: shanksrm@upmc.edu

Savitri Sharma MD

LV Prasad Eye Institute Patia, Bhubaneswar-751024 Orissa, 99370-37298 INDIA P: 91-0674-3987129 / F: 91-0674-3987130 E: savitri@lvpei.org

Edward L Shaw MD 2129 Ridge Drive Los Angeles, CA 90049-1153 E: elshaw123@msn.com

Arthur H Shedden MD

Vistakon Pharmaceuticals LLC 7500 Centurion Parkway, Suite 100 Jacksonville, FL 32256 P: 925-482-5755 / F: 904-928-5805 E: ashedden@its.Jnj.com

Val Shestopalov PhD

Bascom Palmer Eye Institute 1638 NW 10th Ave Miami, FL 33136 P: 305-547-3680 / F: 305-547-3658 E: vshestopalov@med.miami.edu

Alvio I Shiguematsu MD

Rua Darciso Coneglian, 274 Bocaatu-SP, 18608-033 BRAZIL

Megan Shoff PhD

FDA/CDRH/OSEL/DB W064, Rm. 4074 10903 New Hampshire Ave Silver Spring, MD 20993 P: 301-796-0259 E: megan.shoff@fda.hhs.gov

Steven Sicher MD

8921 Wood Sage Road Peoria, IL 61615-7822 P: 309-243-2400 E: ssicher@comcast.net

Andrew Siedlecki BS

Geisel School of Medicine at Dartmouth 30 Wolf Road Unit 405 Lebanon, NH 03766 E: Andrew.N.Siedlecki.Jr.DM@Dartmouth.edu

Daniel N Skorich MD

SMDC 400 E. Third St. Duluth, MN 55804

Alan Slomovic MD

399 Bathurst St. Toronto, Ontario, M5T 2S8 CANADA

Ronald E Smith MD

USC School of Medicine Dept. of Ophthalmology 1450 San Pablo St. Los Angeles, CA 90033 P: 213-342-6424 E: resmith@usc.edu

David A Snyder MD

16201 S. Military Tr. Delray Beach, FL 33484

Michael Snyder MD

1945 Cei Drive CincinnatI, OH 45242 P: 513-984-5133

Membership Roster

New Member 2015 Please send an email with any address changes/corrections to Active Member OcularMicrobiology@gmail.com

Robert W Snyder MD 4711 E. Camp Lowell Dr. Tucson, AZ 857121 P: 520-3272020 / F: 520-881-4396 E: rsnyder@snydereyedoc.com

Rene Solomon MD

One, The Granada Roslyn, NY 11576-1719

Rebecca Sorenson MD

295 Sundown Terrace Orinda, CA 94563 E: rlsorenson@gmail.com

Sarkis Soukiasian MD

Lahey Clinic 41 Mall Road Peabody, MA 01805 P: 978-538-4430 / F: 978-538-4724 E: s.soukiasian@lahey.org

Lucienne B Sousa MD

Rua Estela 121, Apt. 14 Paraiso São Paulo São Paulo, SP BRAZIL

Mark Speaker MD

New York Eye & Ear Infirmary 310 East 14th St., Room 401S New York, NY 10003

Michael B Starr MD

67 East 78 St. New York, NY 10021 P: 212-717-0222 / F: 212-717-0222 E: mbeystarr@aol.com

Jason Stein MD

50 W 57th St, 15th FL New York, NY 10019 P: 212-901-9916 E: jstein@actin.com

Thomas L Steinemann MD

MetroHealth Medical Ctr Division of Ophthalmology 2500 MetroHealth Dr. Cleveland, OH 443109-1998

Nick Stella MD

University of Pittsburgh 203 Lothrop St., 1020 EEI Pittsburgh, PA 15213 P: 412-647-2246 E: stellan@upmc.edu

George Stern MD

Three Rivers Eye Care Center 1200 S Reserve, Suite H Missoula, MT 59801 P: 406-543-9200 E: sternmdga@gmail.com

Scott X Stevens MD

Bend Ophthalmology Inc. 2275 N.E. Doctor's Drive Bend, OR 97701

Donald Stone MD Wilmer Eye Institute King Khaled Eye Specialist Hospital Riyadh, SAUDI ARABIA E: Dstone@kkesh.med.sa

Ralph P Stone MD

6012 Laurel Valley Ct. Ft. Worth, TX 76132

Eric C Strauss Medical Director

Genetech Research & Early Development Exploratory Clinical Development 1 DNA Way MS 45-4B South San Francisco, CA 94080 P: 650-467-8448 E: strauss.erich@gene.com

David W Stroman PhD

NovaBay Pharmaceuticals, Inc. 7214 Native Oak Lane Irving, TX 75063 P: 214-906-1261 E: dwstroman@aol.com

R. Doyle Stulting MD

Woolfson Eye Institute 800 Mt. Vernon Highway, Suite 120 Atlanta, GA 30328 P: 770-255-3330 / F: 770-255-3331 E: dstulting@woolfsoneye.com

Brinda Subbarayal PhD

Schepens Eye Research Institute Massachusetts Eye and Ear Infirmary Department of Ophthalmology Harvard Medical School 20 Staniford Street Boston, MA 02114 E: Brinda_Subbarayal@meei.harvard.edu

Joel Sugar MD

Univ Of Illinois Eye & Ear Infirmary 1855 West Taylor Chicago, IL 60612 P: 312-996-8937 E: joelsuga@uic.edu

Alan Sugar MD

Kellogg Eye Center Dept. of Ophthalmology 1000 Wall St. Ann Arbor, MI 48105-1994 P: 734-763-5506 / F: 734-963-2340 E: asugar@umich.edu

Leejee H Suh MD

Bascom Palmer Eye Institute 900 NW 17th St. Miami, FL 33136 P: 305-326-6147 / F: 305-326-6337 E: lsuh@med.miami.edu

Karen Sumers MD

2575 Peachtree Road, Unit 25E Atlanta, GA 30305 P: 404-261-0040 (h) E: ksumers@gmail.com

John Sutphin MD Univ of Kansas Medical Center Dept of Ophthalmology 7400 State Line Road Prairie Village, KS 66208 P: 913-588-6606 / F: 913-588-0888 E: jsutphin@kumc.edu

R. Geoffrey Sweeting MD

PO Box SS 5380 Nassau, BAHAMAS

Khalid F Tabbara MD

PO Box 55307 Riyadh, 11534 SAUDI ARABIA P: 966-1-462-3094 or 464-9614 F: 966-1-462-9675 E: k.tabbara@nesma.net.sa

Geoff Tabin MD

65 N. Medical Dr. Salt Lake City, UT 84132

Yoichi Takashita MD

1-3-3, Daiwa, Takatsuki Osaka, 569-1049 JAPAN

Mansi Talati, MD

Dept of Ophthalmology/Visual Science The Ohio State University Wexner Medical Center 915 Olentangy River Road, Suite 5000 Columbus, OH 43212 E: mansi.talati@osumc.edu

Audrey Talley MD

10330 Meridian Ave. N., Ste 370 Seattle, WA 98133

Ahmad Tarabishy MD

26851 Tanic Drive, Sutie 102 Wesley Chapel, FL 33544 E: retinasurgeon@outlook.com

Shachae Tauber MD

1229 E. Seminole, Suite 430 Springfield, MO 55804

Hugh Taylor MD

Centre for Eye Research-Australia 32 Gisborne St. East Melbourne VIC, 3002 AUSTRALIA

Jennifer B Taylor MD

4083 17th Street San Francisco, CA 94114 P: 415-608-9782 E: jenniferbtaylor@gmail.com

Mark A Terry MD

Devers Eye Institute 1040 NW 22nd, Ste 200 Portland, OR 97210

Howard H Tessler MD

507 Cambridge Lake Bluff, IL 60044

Membership Roster

New Member 2015 Please send an email with any address changes/corrections to Active Member OcularMicrobiology@gmail.com

Jacob Thomas MD UT Southwestern 3314 Cole Ave., Apt. 149 Dallas, TX 75204 P: 214-717-9748 E: jkt7c5@gmail.com

Christine M Toutain-Kidd PhD

Dept Microbiology & Immunology Vail Bldg, Rm 505 Hanover, NH 03755 P: 603-650-1247 E: christine.toutain@dartmouth.edu

Kimberly D Tran, MD

Bascom Palmer Eye Institute University of Miami 900 NW 17th Street Miami, FL 33136 E: kimberlytran@med.miami.edu

David Truong MD

UT Southwestern Medical Center Department of Ophthalmology 5323 Harry Hines Boulevard Dallas, TX 75390 E: david.truong.md@gmail.com

Julie Tsai MD

343 W. Houston St., Suite 903 San Antonio, TX 78205

Edmund Tsui MD

Dartmouth-Hitchcock Medical Center Section of Ophthalmology 1 Medical Center Drive Lebanon, NH 03756 E: edmund.tsui@dartmouth.edu

Elmer Tu MD

1828 Waterbury Circle Glenview, IL 60025 P: 847-571-3966 / F: 312-355-4248 E: etu@uic.edu

Audrey W Tuberville MD

4560 N Flecha Drive Tucson, AZ 85718 P: 520-529-2361 / F: 520-577-0934 E: tbrville@gmail.com

Catalin Tudora MD

Alcon 6201 South Freeway, T6-7 Ft. Worth, TX 76134

Sonal Tuli MD

1600 SW Archer Road, Rm M120 Gainesville, FL 32610-0284 E: stuli@ufl.edu

Ira J Udell MD

600 Northern Blvd., Suite 214 Great Neck, NY 11021 P: 516-470-2021 / F: 526-470-2000 E: ijudell@aol.com

Russell N Van Gelder MD UW Medicine Eye Institute Box 359608 325 Ninth Avenue Seattle, WA 98104 P: (206) 543-7250 / F: (206) 543-4414 E: russvg@uw.edu

Woodford S Van Meter MD

1760 Nicholasville Rd Suite 203 Lexington, KY 40503-1454 P: 859-275-4001 / F: 859-275-1142

Laura Vickers, MD

Doheny-UCLA Medical Center Department of Ophthalmology 625 South Fair Oaks Avenue, Suite 280 Pasadena, CA 91105 E: olee@doheny.org

Mark C Vital MD

Houston Eye Associates 2855 Gramercy St. Houston, TX 77025

Firoz Vohra MD

Alcon 6201 S Freeman Ft. Worth, TX 76134 P: 817-568-7269 / F: 817-615-3486 E: firoz.vohra@alconlabs.com

Mark Volpicelli MD

24149 Summerhill Avenue Los Altos, CA 94024 E: volpeyes@aol.com

Amit Vora MD

123 Swedes Run Drive Delran, NJ 08075 E: avora80@gmail.com

Michael P Vrabec MD

21 Park Place Appleton, WI 54914 E: mivrabec@aol.com

N. Kevin Wade MD

3794 30th Avenue Vancouver, BC V6S 1W8 CANADA

Hormuz P Wadia MD

10770 N. 46th Street, Suite F Tampa, FL 33617-3459 P: 813-974-5853

Michael D Wagoner MD

1451 Grand Ave. Iowa City, IA 52246 P: 319-356-2861 / F: 319-353-7996 E: michael-wagoner@uiowa.edu

Palak Wall

992 Harrison Avenue Columbus, OH 43201-3325 P: 614-565-6088 E: palak.wall@osumc.edu

Stephen Waller MD 4815 V St. NW Washington, DC 20007-1510 E: stevewaller@rcn.com

Scott Walter MD, MSc

Bascom Palmer Eye Institute University of Miami 900 N.W. 17th Street Miami, FL 33136 E: swalter@med.miami.edu

Arden H Wander MD

222 Piedmont Ave. Suite 1700 ML 665-E Cincinnati, OH 45219

Ming Wang MD

Wang Vision Institute 1801 W. End Ave., Ste 1150 Nashville, TN 37203

John Warren MD

Greenfield Eye Center 33 Ridell Street Greenfield, MA 01301 P: 413-774-7016

Noriko Watanabe MD

Senju Pharmaceutical Co., Ltd. 2-5-6 Hiranomachi-chuuko-0ky Osaka, 541-0046 JAPAN

Robert S Weinberg MD

John Hopkins Bayview Ophth. 4940 Eastern Ave. Baltimore, MD 21224

Michael Weiser MD

50 W 57th St, 15th FL New York, NY 10019 P: 212-901-9916 E: mweiser@actin.com

John Welling MD

Havener Eye Institute The Ohio State University Department of Ophthalmology 915 Olentangy River Road Columbus, OH 43212

Jeff Wells PharmD

26051 Merit Circle, Suite 103 Laguna Hills, CA 92653-7008

Bonnie Weston MD

184 McClellan Rd Ottawa, ON K2H 9A2 CANADA

Jonathan Weyne MD

Ridgeback Capital 430 Park Avenue 12th FL New York, NY 10022

John P Whitcher MD

F.I. Proctor Foundation 95 Kirkham St. San Francisco, CA 94143-0944 P: 415-731-1075 E: jack.whitcher@ucsf.edu

Membership Roster

New Member 2015 Please send an email with any address changes/corrections to Active Member OcularMicrobiology@gmail.com

Clayton Whitney MD 2440 E. 5th St. Tyler, TX 75701-3592

Lee Wiley MD

West Virginia Eye Institute Stadium Drive, PO Box 9193 Morgantown, WV 26506-9193 P: 304-598-6441 / F: 304-598-6928 E: wileyl@wvuh.com

Kirk R Wilhelmus MD

3250 Locke Lane Houston, TX 77019 E: kirkw@bcm.edu

John Williams MD

18 Erin Office Park Dublin, GA 31021

Stephen Wilmarth MD

NovaCal Pharmaceuticals 1830 Sierra Gardens Dr., Ste 100 Roseville, CA 95661 E: md@wilmartheye.com

Karen Winchester MD

3802 SE Schools Ferry Rd. Portland, OR 97221

John R Wittpenn MD

4 Technology Drive, Suite 150 East Setauket, NY 11733-4068

Ira G Wong MD

Proctor Foundation, UCSF 95 Kirkham St.. San Francisco, CA 94122 E: ashokkumar@lvpei.org

I-Hui E Wu MD

Ophthalmic Consultants 310 East 14th St. New York, NY 01003 P: 212-505-6550 E: ewu@nyee.edu

J.L. Wupper MD

PO Box 66159 Houston, TX 77266-6159

Renee Yang MD

1650 Response Road Sacramento, CA 95815-4807 E: ryang260@yahoo.com

William Yeakley MD

Summit Ophthalmology, Inc. One Park West Blvd., Suite 150 Akron, OH 44320 E: wyeakley@roadrunner.com

Gerald W Zaidman MD

Westchester Med Ctr Ophthalmology, Macy Bldg Valhalla, NY 10595 P: 914-493-1599 / F: 914-493-7445 E: pedkera@aol.com

Michael Zegans MD Dartmouth Hitchcock Medical Ctr Ophthalmology Lebanon, NH 03756 P: 603-650-5123 / F: 603-650-4434 E: mez@dartmouth.edu

Steven Zhang MD

Bausch & Lomb Pharmaceuticals 376 Rockedge Drive Oak Park, CA 91377 P: 818-292-0730 / F: 866-299-1242 E: steven.zhang@bausch.com

Leonid Zlotcavitch BA

Bascom Palmer Eye Institute University of Miami 900 N.W. 17th Street Miami, FL 33136 E: lzlotcavitch@med.miami.edu